In silico comparison of photons versus carbon ions in single fraction therapy of lung cancer by Anderle, Kristjan
In Silico Comparison of Photons
versus Carbon Ions in Single
Fraction Therapy of Lung Cancer
In Silico Vergleich der Lungen Krebstherapie mit Photonen und Kohlenstoff Ionen bei
Einzeitbestrahlung
Zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.)
genehmigte Dissertation von Dipl.-Phys. Kristjan Anderle aus Jesenice, Slowenien
Darmstadt 2016 — D 17
Fachbereich Physik
1. Gutachten: Prof. Dr. Marco Durante
2. Gutachten: Prof. Dr. Thomas Aumann
In Silico Comparison of Photons versus Carbon Ions in Single Fraction Therapy of Lung Cancer
In Silico Vergleich der Lungen Krebstherapie mit Photonen und Kohlenstoff Ionen bei Einzeitbe-
strahlung
Genehmigte Dissertation von Dipl.-Phys. Kristjan Anderle aus Jesenice, Slowenien
1. Gutachten: Prof. Dr. Marco Durante
2. Gutachten: Prof. Dr. Thomas Aumann
Tag der Einreichung: 14. Juni 2016
Tag der Prüfung: 4. Juli 2016
Darmstadt — D 17
Abstract
Stereotactic body image guided radiation therapy (SBRT) shows excellent results for the local
control of early stage lung cancer. However, not all patients are eligible for SBRT, and advanced
stage treatment is less successful and often associated with severe side effects. Scanned carbon
ion therapy (PT) can deliver more conformal dose likely benefiting these patient groups.
Therefore an in silico trial was conducted on early and advanced stage patients to identify
potential advantages of PT. The patients were treated with SBRT at Champalimaud Center for
the Unknown, Lisbon (Portugal). PT plans were simulated on 4DCTs, and rescanning was in-
vestigated for motion mitigation in 4D-dose calculations. A dedicated strategy for 4D intensity
modulated particle therapy (IMPT) was developed and applied for advanced stage patients with
multiple lesions. For clinically valid and reliable results the deformable image registration -
necessary for 4D-dose calculation - a quality assurance tool was developed and applied in the
study.
The results showed that target coverage was comparable in SBRT and PT, while PT delivered
significantly lower doses to most critical structures, especially the heart, lungs, and esophagus.
A highly complex case of advanced stage lung cancer could be treated in a single fraction of
24 Gy with PT, while SBRT could not deliver the full ablative dose treatment due to an excessive
heart dose. The mean heart dose was reduced from 10 Gy to 0.8 Gy with PT for this specific
patient.
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Zusammenfassung
Stereotaktische Radiochirurgie (SBRT) zeigt exzellente Ergebnisse für die lokale Kontrolle von
Lungenkrebs im Frühstadium. Viele Patienten sind allerdings nicht für die SBRT geeignet, und
die Behandlung von späteren Stadien führt oft zu schweren Nebenwirkungen. Die Bestrahlung
mit gescanntem Kohlenstoff (PT) ermöglicht eine konformere Dosisapplikation, wovon gerade
diese Patientengruppen profitieren könnten.
Eine in silico Studie an Lungenkrebspatienten in frühen und späten Stadien wurde durchge-
führt, um mögliche Vorteile von PT zu untersuchen. Die Patienten wurden am Champalimaud
Center for the Unknown, Lissabon (Portugal) mit SBRT behandelt. PT Pläne wurden auf 4DCTs
simuliert und zur Bewegungskompensation wurde Rescanning in 4D-Dosisberechnungen unter-
sucht. Eine dedizierte Strategie für 4D Intensitäts-modulierte Partikeltherapie (IMPT) wurde
entwickelt und für Patienten im fortgeschrittenem Stadium mit mehreren Läsionen eingesetzt.
Für klinisch valide und verlässliche Ergebnisse wurde für Nicht-rigide Bildregistrierung - für
die 4D-Dosisberechnung unerlässlich eine Strategie zur Validierung und Qualitätssicherung en-
twickelt.
Es ergab sich eine vergleichbare Dosisabdeckung der Ziele für PT und SBRT, mit PT konnte
die Dosisbelastung fast aller Risikoorgane aber signifikant gesenkt werden, insbesondere des
Herzens, der Lunge und der Speiseröhre. In einem besonders komplexen Fall von Stufe IV
Lungenkrebs konnte PT alle 5 Läsionen mit der vollen Dosis von 24 Gy abdecken, während dies
mit SBRT durch die zu hohe Herzdosis nicht möglich war – die mittlere Herzdosis konnte mit
PT trotz voller Zieldosis von 10 Gy auf 0.8 Gy reduziert werden.
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Motivation
In 2013 every fourth death in Germany was due to cancer and approximately 45 000 deaths
were from lung and bronchial cancer [German Federal Statistical Office, 2015]. In the last 30
years, there was a 180% increase of deaths due to lung and bronchial cancer for women. The
standard course of treatment for lung cancer is surgery, chemotherapy, radiotherapy or a com-
bination of these. Surgery is usually the first choice of treatment for early stages of lung cancer.
In recent years, however, state of the art photon radiotherapy, called stereotactic body-radiation
therapy (SBRT) showed promising results [Baumann et al., 2009, Greco et al., 2011]. The core
innovation of SBRT was to deliver high ablative and focused doses in very few fractions, usually
1 – 5, compared to up to 30 fractions in conventional radiotherapy. Due to the high fraction
doses up to 24 Gy, dose to critical structure must be considered carefully.
In the last twenty years, ion beam therapy has proven to be a promising alternative
to photon radiotherapy. Higher tumor control rates and better dose conformity can be
achieved with superior physical and biological ion properties, when compared to photons
[Tsujii et al., 2008, Durante and Loeffler, 2010]. A recent review made by Kamada et al re-
ported a high 3-year survival rate for carbon-ions (76.9%) for treating lung cancer in a single
fraction, with no late treatment-related complications [Kamada et al., 2016]. The treatment
used passive beam scanning, where patient specific absorbers are used to conform the dose to
the tumor. Active beam scanning, on the other hand, can provide even better dose shaping,
which is essential in hypo-fractionated treatment. However, interaction between tumor and
scanned beam motion, called interplay, can severely degrade dose distribution in the breath-
ing patient. Therefore designated motion mitigation techniques must be used for successful
treatment of lung cancer with active beam scanning [Bert et al., 2008].
Tumors in the abdomen region (liver and pancreas tumors) with were already success-
fully treated scanned ion beams at HIT, Heidelberg (Germany) and CNAO, Pavia (Italy)
[Habermehl et al., 2013, Rossi, 2016] and first lung cancer patients are being treated at NIRS,
Chiba (Japan) [Mori et al., 2016]. Studies on impact of scanned ion beams on lung cancer
treatment are thus warranted, so that eligible patients can be identified. This is crucial, as ion
therapy is expensive and clinical availability is limited – its application should thus be focused
on patients who will benefit the most.
In this thesis, we will address this challenge of treating lung cancer patients with active beam
scanning in a direct comparison between SBRT and scanned carbon-ion therapy. Characteristics
of patients particularly suited for carbon-ion therapy will be identified for a possible future
treatment at designated facilities in Marburg and Heidelberg.
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Scope of this work
This is the first in silico comparison between SBRT and active scanning carbon-ion for non-small
cell lung cancer (NSCLC). Time-resolved (4D) dose distributions will be studied on a large
patient dataset, including patients with multiple metastases.
In order to create carbon-ion treatment plans and calculate 4D doses, contours have to be
propagated from the planning computed tomography (CT) to all motion states of a 4D-CT. Ad-
ditionally, motion between 4D-CT states has to be quantified, and doses have to be accumulated
on a reference state. This will be achieved with deformable image registration (DIR). DIR is
a powerful image processing tool, but is based on large degrees of freedom and consequently
associated with a large potential for error. Especially the propagation of dose with DIR is a
highly debated issue in current research. Therefore, a designated tool for DIR quality assurance
(DIRQA) will be developed. A verification of DIR and DIRQA will be done on available 4D-CT
datasets.
To show the potential of scanned carbon-ions in handling NSCLC, treatment plans for 19
patients, which were actually treated with SBRT, will be calculated. Afterwards, static and 4D
doses with and without motion mitigation will be analyzed. Doses to targets and organs-at-risk
(OAR) will be analyzed and compared between carbon-ions and SBRT.
Patients with advanced stage disease and multiple lesions in the lungs have an exceptionally
dismal prognosis. A strategy to apply intensity modulated particle therapy on multiple targets
will be developed and implemented in the GSI in-house treatment planning system TRiP98.
Different 4D optimization strategies will be tested in a dataset of such patients to cope with
target motion in this specific setting. Again, plans will be compared to actually delivered SBRT
doses, both with respect to reduction of normal tissue exposure, but also to investigate whether
PT can deliver full ablative doses to these patients where SBRT could not due to normal tissue
constraints.
The structure of this dissertation is as follows. Chapter 1 will present an overview of physical
and biological fundamentals of radiotherapy. Photon and particle radiotherapy will be pre-
sented, with an emphasis on the treatment of moving targets. Additionally, a description of lung
cancer will be given. Chapter 2 will present tools to handle DIR and DIRQA and verification of
these tools. In chapter 3, comparison between SBRT and carbon-ions will be investigated on
lung cancer patients. IMPT for patients with multiple metastases in lung will be investigated
in chapter 4. Overall results will be discussed in chapter 5 and the thesis will be concluded in
chapter 6.
11

1 Introduction - research background and
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1.1 Radiotherapy
Ionizing radiation has been used for treating tumors since the discovery of X-rays in 1895. In
the beginning, only superficial diseases were treated, but as time and technology progressed
X-ray tubes gained on voltage, allowing treatment of deeper seated tumors.
The radiation from a linear accelerators was first used in medicine in 1953. The cure rates in-
creased tremendously due to the collimated beam and higher energies compared to X-ray tubes.
The next big milestone was the introduction of computers in the field of radiotherapy. This led to
better diagnostic tools, such as computed tomography scans (CT), magnetic resonance imaging
(MRI) and positron emission tomography (PET). The location of the tumor could be estimated
better with these tools and hence the treatment was improved. The potential of computers was
afterwards exploited also in the treatment planning process, resulting in intensity modulated
radiation therapy (IMRT) which, together with diagnostic tools, provides an exact dose shaping
in accordance to patient specific tumors.
In 1946, a paper from R. Wilson first described the application of protons for cancer treatment
[Wilson, 1946]. It was shown that protons have a preferable depth dose profile compared to
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photons. First patient treatment followed in the early 1950’s at Lawrence Berkeley Laboratory,
USA. Heavier ions, such as 2He, 20Ne and 6C were later also used for treatment. In the begin-
ning only passive beam delivery (see Section 1.2.3) was used for treatment and a active beam
solution (see Section 1.2.3) was developed in the 1990’s at Paul Scherrer Institute (PSI), Villigen
(Switzerland) for protons and at GSI, Darmstadt (Germany) for carbon ions.
1.2 Physical and biological basics of radiotherapy
The aim of radiotherapy is to kill tumor cells and prevent further growth, while sparing healthy
tissue. Both radiotherapy modalities (photons and ions) use the same principle to eliminate
cancer cells - they aim to damage the deoxyribonucleic acid (DNA) through ionization. The
actual physical and biological mechanism behind both modalities will be explained in detail in
the following section.
1.2.1 Interaction of radiation with matter
The interactions between photons with matter and ions with matter are quite different, as can
be seen from depth dose distributions in Fig. 1.1. Photons deposit the highest local dose shortly
after entering the matter (at the energies used in radiotherapy). Ions, on the other hand, deposit
most of their dose right before they stop in the so-called Bragg Peak region. The position of the
Bragg Peak depends on the energy of the ions, which is exploited in the treatment of deep seated
tumors.
Dose definition
An important quantity in radiotherapy is dose, D, defined as the ratio of the absorbed energy
dE per mass element dm [ICRU, 1993b]:
D =
dE
dm

G y =
J
kg

(1.1)
Energy loss in a thin layer of material is described as dE/d x . Dose can be then rewritten as:
D =
dE
d x
× 1
F
× 1
ρ
(1.2)
where F is the fluence and ρ the material density.
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Figure 1.1.: Photon and carbon ions depth dose distributions at different energies. Photons start
with a build up, which is then followed by an exponential decrease. Ions deposit
most of the dose at the end of the particle track - the Bragg peak. Figure taken from
[Schardt et al., 2010]
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Interaction of photons with matter
Photons mostly interact with matter in one of the following ways: coherent or Rayleigh scat-
tering, photoelectric effect, Compton scattering and pair production. The cross section σ, for
each of these processes depends as well on the energy of the incident photons as on the atomic
number of the absorbing material [Lilley, 2006]. The decreasing photon intensity in matter, I ,
can be described as:
I = I0 · e−Nσx = I0 · e−µx (1.3)
where I0 stands for the initial intensity of the photons, x the depth of the material in units of
length, N the atomic density of the material and µ the attenuation coefficient. The cross section,
σ is the sum of all possible Interaction processes:
σ = σra ylei gh+σphotoelec t r ic + Zσcompton+σpairproduct ion (1.4)
The energy range of photons used in radiotherapy is between 100 keV and 25 MeV. The domi-
nating process in this energy range is Compton scattering [Alpen, 1998]. The electrons resulting
from Compton interaction scatter mostly in a forward direction. Therefore a maximum of the
depth-dose profile occurs when electrons stop at a certain depth, the mean electron range. After
this build up the dose deposition decreases exponentially (see Fig. 1.1 and Equation 1.3).
Interaction of ions with matter
Ions can interact with matter either with elastic Coulomb scattering from target nuclei (nu-
clear stopping) or with inelastic collision with target electrons (electronic stopping). At the ion
energies used in radiotherapy, which are less then 500 MeV/u, the electronic stopping is the
dominating interaction. The result is ionization and excitation of the target atoms.
The mean rate of the ions energy loss in matter is described by the Bethe-Bloch formula
[Bethe, 1930, Bloch, 1933]. Since we are interested in low ion energies, a non-relativistic ap-
proximation can be made:
−

dE
d x

=
4piNez
2
e f f
mev
2

e2
4piε0
2
ln

2mev
2
I

+ cor rect ion

(1.5)
here Ne is the material’s electron density, e and me are the charge and mass of an electron, ε0
the electrical field constant and I the mean excitation energy of the absorber material. Barkas
formula [Barkas, 1963] can be used for the approximation of the effective projectile charge ze f f :
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ze f f = z

1− e−125βz
2
3

(1.6)
where β is the projectile speed in units of c.
The energy loss of the ions is proportional to ze f f and inversely proportional to v
2. The
shape of the curve in Fig. 1.1 can be explained as following: Ions enter the matter with a high
velocity, resulting in a small energy deposition. Their velocity gradually decreases, which in
turn increases the energy deposition. The maximum of the energy loss occurs right when the
ions stop and it is called Bragg peak.
Lateral scattering and range straggling of ions
As mentioned ions interact with matter mostly via electronic stopping at energies used in radio-
therapy. However, nuclear stopping still occurs and it is the main reason for lateral scattering.
The angular spread of ions is dependent on the mass of the target nuclei and on the momentum
of the incident ions [Molière, 1948]. The lateral scattering is proportional to the mass of the
target nuclei and inversely proportional to the momentum of incident ions. Carbon ions have
thus less lateral scattering then protons. Experiments have shown that carbon ions have three
times smaller angular spread compared to protons at the same range in water (15.6 cm, 150
MeV/u protons and 285 MeV/u 12C ions) [Schardt et al., 2010].
Statistical fluctuations of specific electronic stopping events cause range straggling of ions.
If the number of collisions is high or the material is thick enough these fluctuations can be
approximated by a Gaussian probability distribution [Bohr, 1940, Ahlen, 1980]. The straggling
width σR is proportional to:
σR ∝ R/
p
M (1.7)
where R is the mean range of ions and M the ion mass. Thus, the heavier the ion is, the
less range straggling it has. Carbon ions have 3.5 smaller range straggling when compared to
protons [Schardt et al., 2010].
Nuclear fragmentation
When transversing through matter ions (except protons) can be fragmented into ions with lower
atomic number. The lower Z fragments travel in the same direction as projectile ions and have
a significant contribution to the deposited dose (see Fig. 1.2). It is thus essential that fragments
are included in the treatment planning, so that an accurate dose can be calculated.
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ent models [Chatterjee and Schaefer, 1976, Katz and Cucinotta, 1999] and Monte Carlo simu-
lations [Paretzke, 1986, Krämer, 1995] predict radial dose fall-off approximately with 1/r2 for
radial distance r. Varma et. al. have confirmed this experimentally [Varma et al., 1977]. The
maximum radial distance rmax is defined by the most energetic δ-electrons, which are related
to energy, E, of the projectile ions [Kiefer and Straaten, 1986].
rmax = E
1.7 (1.8)
Following equation 1.5, E is correlated to Z2 and 1/β2, meaning that track structure is highly
dependent on the projectile ion species and the energy as demonstrated in Fig. 1.3: Carbon
ions have a denser ionization structure compared to protons [Krämer and Durante, 2010]. δ-
electrons have low energies, and thus the r is on nanometer scale. As the energy of projectile
ions decreases, their stopping power increases and causes significantly larger number of δ-
electrons. The energy deposited by δ-electrons in medium is described using the linear energy
transfer (LET), which is closely related to dE/d x . Fast ions with low ionization have a small
LET, while slow ions with a large ionization have a high LET.
1.2.2 Radiobiology
Ionizing radiation (photons and ions) causes damage throughout the cell. However the most
susceptible part to radiation is the carrier of genetic information, the DNA, located in the cell
nucleus [Munro, 1970]. Radiation can damage DNA directly or indirectly.
Ionization and consequent destruction of DNA molecular bonds via radiation is a direct effect
(see Fig. 1.4b) and is typical for high-LET radiation. On the other hand, an indirect effect is
when radiation hydrolysis water around DNA and produce highly reactive hydroxyl-radicals,
OH (see Fig. 1.4a). Even though OH radicals decay fast, they are still able to cause severe
damage to DNA. The formation of OH is typical for low-LET radiation like photons. The two
processes, direct and indirect, are not exclusive and can damage DNA in parallel.
19

Figure 1.4.: Types of DNA damage caused by radiation (a) Indirect damage occurs, when radia-
tion forms free radicals hydroxyl radicals (OH), which can damage DNA. (b) Direct
effects of radiation can cause single or double-strand breaks. Figure taken from
[Richter, 2012]
Damage to DNA can result in either single strand breaks (SSB) or double strand breaks (DSB)
as shown in Fig. 1.4b). When one of the double strands in the DNA helix is destroyed (SSB),
it can usually be easily repaired by cell repair-mechanisms, since the complementary base is
intact. If both strands are destroyed (DSB) the DNA damage is much more complex and leads
to the breakage of the chromatin. The cell repair-mechanisms can handle DSB as well, albeit
not as efficient as SSB. However if there are clustered DSBs, the damage is usually too severe
for repair-mechanisms to undo it. The changes in damaged DNA can lead to carcinogenesis
or cell death. The aim of radiotherapy is to cause an apoptosis - a controlled self-inactivation
of the cell triggered by the DNA damage. Beside apoptosis, cell can also undergo necrosis, an
uncontrolled cell death. Cell necrosis often causes response from the immune system, leading
to inflammation, which radiotherapy strives to avoid. DNA can also be damaged to such extent,
that cell cannot proliferate indefinitely - a effect known as clonogenic cell death.
Relative Biological Effectiveness
Fig. 1.3 shows the size of a DNA molecule in comparison with proton and carbon ion distribution
of δ-electrons around their track. A clustered DSB occurs preferably around the Bragg peak
due to large ionization densities. Less cells will survive a clustered DSB, compared to DSB or
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SSB. Ions have large ionization density, which is one of the main advantages over photons in
radiotherapy. Since most of the clinical experience about cell response to radiation comes from
photons, the biological effect of ions is usually described relative to a reference photon response.
Relative biological effectiveness (RBE) is therefore defined as the ratio of the reference photon
dose to the dose level of a specific ion radiation at the same biological effect (isoeffect):
RBE =
D
re f
photon
Dion

isoe f f ec t
(1.9)
It is important to note at this point that RBE values are valid only for the same effect - the
same biological endpoint and the same reference radiation. The most interesting biological
endpoints in radiotherapy are cell survival and side effects. RBE values are usually obtained
from cell survival curves (see Fig. 1.5). Cell survival, S, is commonly modeled by an exponential
linear-quadratic (LQ) model [Fowler, 1989]:
S(D) = e−αD−βD
2
(1.10)
α is a coefficient related to a single event cell killing and β coefficient related to a double event
cell killing. The ratio of α/β is a characteristic of the cell type, namely the tissue capacity to
repair radiation damage. A small α/β ratio means a cell is radioresistive (high repair capacity)
and vice versa. As seen in Fig. 1.5 and Eq. 1.10, RBE values are dependent on the dose level.
Hence in ion radiotherapy, beside the physical absorbed dose, a photo-equivalent or biological
dose incorporating the RBE also plays an important role. The unit for biological dose is Gy
(RBE) [ICRU, 2007].
Besides the dose level, RBE also depends on the LET, the particle species and the tissue type
[Kraft, 2000]. Therefore RBE modeling is a complex topic. At GSI, RBE is calculated using
the local effect model (LEM) developed by Scholz et al. [Scholz and Kraft, 1994]. There are two
main assumptions in the LEMmodel. The first is that localized biological effects are independent
on the radiation type. The second assumption is that the photon response is the same for all dose
levels (high and low). The difference between different radiation types comes from the dose
deposition in a small volume in the cell nucleus. At the same total dose, many photons create a
homogeneous dose distribution over a cell nucleus, while few ions cause a highly localized dose
distribution around their track.
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Figure 1.5.: Typical cell survival curve for photons (black solid line) and heavy ions (red dashed
line). Photon line shows a typical shouldered form, described by the linear-quadratic
model. Heavy ions show a much steeper decrease with dose. The RBE value can be
calculated by looking at the dose values at the same survival value - corresponding
to the same biological effect. Figure taken from [Schardt et al., 2010]
LEM can thus predict dose response, by comparing photon response at the high local
dose level. LEM was used in the GSI pilot project from 1998 - 2007 [Krämer et al., 2000,
Krämer and Scholz, 2000] as well as clinically in HIT since 2009. LEM has received several re-
visions [Elsaesser and Scholz, 2006, Elsaesser and Scholz, 2007, Elsaesser et al., 2009] and ex-
perimental verifications [Mitaroff et al., 1998, Krämer and Scholz, 2000, Krämer et al., 2003].
RBE for carbon ions ranges from 1 in the entrance channel, to values around 5 at the Bragg
peak [Kraft, 2000]. The highest RBE for carbon ions is right around the Bragg peak, which gives
carbon ions a great advantage, since there is an increased biological effectiveness at the target
tissue compared to the normal tissue in the entrance channel. In proton therapy a constant RBE
value of 1.1 across the treatment field is used [Paganetti et al., 2002].
Fractionation
Radiotherapy applies a basic principle of radiobiology that dose fractionation spares all cell
types. For a given total dose more cells will survive with dose delivered across multiple fractions,
compared to a single dose, because cells will have time to repair radiation induced sub-lethal
damage between fractions. With a dose d delivered over n fractions, equation 1.10 can be
rewritten as [Shrieve and Loeffler, 2011]
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S = (e−αd−βd
2
)n (1.11)
The biological effective dose (BED) is defined as:
BED(G yα/β) = nd

1+
d
α/β

(1.12)
with the total dose D equal to n× d, we can define the fractionation factor F as
F =

1+
d
α/β

(1.13)
so that BED = D×F . F increases with d, but decreases with α/β . Lower α/β (late-responding
tissue) means higher F and a higher α/β (early responding tissue) moves F towards 1. As nor-
mal tissue typically has a lower a/b (around 2) than tumor tissue (around 4-10), fractionation
effectively increases the differential dose to the tumor, and thus increases the therapeutic win-
dow.
Hypofractionation
Due to the improvement in radiotherapy, there is a trend to increase the dose per fraction and
reduce the number of fractions, called hypofractionation [Lo et al., 2010]. Hypofractionation
consists of 1-3 fractions of high doses, up to 24 Gy in a single fraction (single-dose). It has
shown promising results over a wide range of tumors [Yamada et al., 2008, Greco et al., 2011,
Halasz and Rockhill, 2013]. The high dose damages the vascular system, which supplies can-
cer tissue with oxygen and nutrients. The damage to the vascular system and may be the
dominant process in the tumor suppression [Fuks and Kolesnick, 2005]. This was originally
showed in genetically modified mice, where vascular damage was shown for doses higher than
10 Gy per fraction [Garcia-Barros et al., 2003]. Effect of high doses on vascular system and
consequential tumor control was later confirmed in spinal SBRT for doses between 18-24 Gy
[Yamada et al., 2008].
While the effect of high doses on the vascular component is apparent, a strong effect of hy-
pofractionation can also be explained with a high BED resulting from the LQ model, as shown in
Table 1.1. The radiation to normal tissue limited the use of hypofractionation in the past. Most
recent photon therapy, SBRT, can significantly reduce the normal tissue radiation and hence in-
crease the dose per fraction. The scientific community has not yet reached consensus on which
mechanism is actually at work behind hypofractionation [Park et al., 2012a].
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In addition to high tumor control rates, hypofractionation is also beneficial from economical
point of view. If the number of fractions is reduced, i.e. from 30 to 1-3, the treatment time and
hence the cost is tremendously reduced, which is especially important in PT.
Table 1.1.: BED for different fractionation schemes for two α/β ratios. Single fraction (1 x 24
Gy) has more than two times higher BED compared to conventional (30 x 2 Gy) or 3
x 9 Gy fractionation scheme for α/β = 2.
Fractionation scheme
1 x 24 Gy 3 x 9 Gy 5 x 7 Gy 30 x 2 Gy
BED (Gyα/β=6) 120 68 76 80
BED (Gyα/β=2) 312 149 158 120
1.2.3 Application technique
The use of X-rays for treating patients has more than a century long history. There is a lot of
research and practical knowledge regarding the clinical usage of X-rays. Particle therapy, on
the other hand, is a more novel technique, with more patients being treated every year. In the
following sections an overview will be given of how the irradiation is actually delivered to the
patient for both modalities with the emphasis on ion therapy.
Photon therapy
In photon therapy high energy x-rays (MV) are used for tumor irradiation. X-rays are produced
in a linear accelerator (LINAC). Electrons are accelerated with energies from 2-25 MeV and
collided with a high-density target (tungsten), where x-rays are produced via bremsstrahlung.
The beam is then directed to the patient and conformed to the tumor shape. The beam is shaped
either by blocks at the head of the machine or by a multileaf collimator. A multileaf collimator
is made of individual leaves, that can be moved to represent the tumor’s shape in the beam’s
eye view, see Fig. 1.6.
Linear accelerators are usually placed on a gantry, which can be rotated around the patient
allowing irradiation from any angle. The arbitrary choice of the beam angle is used in a 3-
dimensional conformal radiotherapy, where a variable number of beams is used. Each beam is
then shaped with a multileaf collimator. An even more precise technique is intensity-modulated
radiotherapy (IMRT). IMRT allows treating complex tumor shapes, e.g. when the tumor is in
proximity of a critical structure. Volumetric modulated arc therapy (VMAT) uses continuous
irradiation together with continuous gantry rotation and multileaf collimator shaping. VMAT is
able to produce even more conformal dose shapes than IMRT.
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Passive beam shaping
The general idea of passive beam shaping is to transform a beam of a fixed single energy into
the shape of the tumor. This is done in several steps as schematically shown in Fig. 1.7. Firstly,
the beam is broadened using a scattering device (passive double scattering systems or magnetic
wobbler) in order to obtain a broad, flat profile. In the next step, the beam is spread out over the
required energy range with a range modulator. Usually a range modulator consist of rotating
wheels of various thicknesses or a ridge filter [Chu et al., 1993]. A beam of fixed energy is
thus expanded into a so-called spread-out Bragg peak (SOBP), which is moved to the required
depth using a range shifter. The final two devices in the beam’s path are built for each patient
individually. A collimator shapes the beam in a lateral direction, while a compensator adjusts
the SOBP to the distal edge of the tumor. However, a compensator cannot adjust the dose in the
proximal ledge of the tumor, resulting in an access dose to the healthy tissue (hatched area in
Fig. 1.7).
Passive beam shaping offers a more robust and faster treatment delivery in contrast to ac-
tive beam shaping. However, it lacks tumor conformity, the dose cannot be modulated and
each patient needs individually tailored devices for each beam used in the treatment. Further-
more, the beam travels through some material, exposing the patient to additional dose due to
fragmentation.
Active beam shaping
In contrast to passive beam shaping, active beam shaping works by dividing the tumor into small
points, which are then irradiated using a thin pencil beam. The tumor is first segmented into
iso-energy slices (IES) and each of IES is covered with a 2 dimensional grid (raster points). A
thin pencil beam is deflected from raster to raster point, irradiating each one with designated
dose. The technique allows irradiation of arbitrary shape, without introducing any additional
patient specific hardware. The lack of additional material in front of the patient also means less
dose due to lesser neutron flux. Furthermore, the dose modulation in each point allows a highly
conformal dose distribution with less dose deposited to the healthy tissue.
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Figure 1.7.: Schematic presentation of a passive beam shaping. A scattering system is used to
broaden the beam. Afterwards a range modulator spreads out Bragg Peak to the
required energy range. The spread out the Bragg peak is then shifted to a specific
energy with a range modulator. Finally, a patient specific collimator and conforma-
tor serve for lateral and longitudinal conformity, respectively. The proximal edge of
the tumor cannot be shaped, as shown with the hatched area. Figure taken from
[Schardt et al., 2010].
There are differences in specifics of active beam shaping. The GSI system of the
three-dimensional scanning system will be given here [Haberer et al., 1993, Kraft, 2000,
Schardt et al., 2010] and a schematic presentation is shown in Fig. 1.8 and Fig. 1.9. A syn-
chrotron provides a thin pencil beam of 12C ions with a variable energy in the range of 30 -
400 MeV/u. The energy defines the position of the Bragg peak in depth. Fig. 1.9b shows how
the Bragg peaks are stacked in depth to cover the longitudinal extension of the tumor. The thin
pencil beam is guided by two magnetic deflection units to irradiate each raster point. The spe-
cific dose in each raster point is calculated in the treatment planing. During treatment the beam
stays on each raster point until the intensity monitoring system measures the designated dose.
Then it is moved to the next raster point. When the whole IES is irradiated the beam extraction
is aborted and the accelerator delivers the next energy for the following IES.
Fig. 1.9a displays how the dose homogeneity in the target is achieved. To achieve flat dose
distribution with a Gaussian beam profile, the beam’s full width half maximum is three times
the lateral raster spacing. Such configuration offers robustness for uncertainties of the beam
spots. The spacing between individual IES is usually 3 mm, providing enough overlap between
individual Bragg peaks. However, the number of IES should be kept low, since the changing
of the beam energy takes most of the time and hence prolongs the treatment. Instead of using
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1.2.4 Motion in radiotherapy
The patient motion can have a profound effect on the radiotherapy. It can cause large deviations
from the planned dose, resulting in under- or over-dosage in target and excess dose in OAR. The
motion type, its extent and origin is therefore a vast topic of research. A brief introduction will
be given here, for an in-depth explanation the reader is pointed to the review by Langen and
Jones [Langen and Jones, 2001].
Motion types
There are three main types of motion: patient positioning, inter- and intra-fractional motion.
All three motion types are shown in Fig. 1.10.
Patient position varies between image acquisition (e.g. CT) used for treatment planning and
actual delivery. The patient motion introduces changes in tumor shape and tumor position.
To overcome patient position uncertainties, patient immobilization and dedicated protocols are
used.
Interfractional motion happens between two treatment sessions (fractions) and results in
anatomical changes in a patient. It occurs on a time scale of hours and days. For lung cancer pa-
tients, the tumor shrinks and the lung density can change between fractions [Mori et al., 2009].
Also changes in breathing pattern can impact treatment delivery. Additionally, the tumor base-
line drifts significantly [Sonke et al., 2008]. Repeated imaging and replanning reduces the im-
pact of the interfractional motion, but requires additional time.
Intrafractional motion is mainly caused by respiration and heart beat, but also peristalsis. The
time scale ranges from seconds to minutes. In this thesis we investigated the treatment of lung
cancer, focusing on respiratory motion. Respiratory motion varies from patient to patient and
is responsible for tumor motion from a mm range to a couple of cm [Shirato et al., 2004]. The
tumor size and T-staging are also correlated to tumor motion [Liu et al., 2007]. The respiratory-
induced motion is largest in superior-inferior (SI) direction rather than in the anterior-
posterior (AP) or left-right (LR) directions [Seppenwoolde et al., 2002, Britton et al., 2007,
Liu et al., 2007].
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Figure 1.10.: Examples of the three major motion categories. On the left side (a) a lung tu-
mor is displayed, which moves due to the respiration of the patient (intrafrac-
tional motion). Interfractional position changes are exemplary shown in the
middle (b), where two CT scans of a prostate patient are compared. Den-
sity variations between two CT scans are shown in (c). Figure taken from
[Engelsman and Bert, 2011]
Motion mitigation techniques
While all three motion types have to be addressed in treatment planning, special focus will
be given on intrafractional motion mitigation. Photon radiotherapy or particle radiotherapy
with passive beam shaping use larger safety margins to encompass the whole tumor motion as
explained in Section 1.2.5. However, larger safety margins are not enough to mitigate motion
when active beam shaping is used. The beam delivery sequence and the target motion interfere
with one another, resulting in over- and underdosages in patients. This effect is called interplay
and it has been thoroughly reviewed elsewhere [Phillips et al., 1992, Bert et al., 2008]. The
effect of interplay depends on many factors, such as motion amplitude, beam direction, starting
breathing phase etc. Three main techniques are currently established to counteract interplay:
rescanning, gating and beam tracking. Several others techniques exist to reduce the effect of
tumor motion, such as abdominal compression, jet ventilation, apneic oxygenation etc., but will
not be described here, since the scope of this thesis is on free-breathing patients.
Rescanning is a technique that uses statistical averaging of different interplay patterns
[Phillips et al., 1992]. Instead of applying the whole dose D at once, the target is scanned
N times, each time irradiated with D/N. The result is a Gaussian dose distribution around D
with no interplay (static case), as shown in Fig. 1.11. With more rescans (larger N), better dose
homogeneity is achieved, because the variance is proportional to 1/N. Technically the method
is the easiest to implement of the three mentioned, since no real-time motion monitoring is
necessary. The treated volume must be enlarged to at least encompass the target in all motions
states (in contrast to gating), which introduces additional dosage to normal tissue. Rescanning
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is currently used at NIRS, Tokyo (Japan) and at some proton centers.
Figure 1.11.: Film irradiation with rescanning. With statistical averaging of multiple interplay
patterns the dose in the target (solid red square) becomes homogeneous. Figure
taken from [Bert et al., 2009].
Gating applies irradiation only in a selected part of the breathing cycle in a so-called gat-
ing window (GW) [Minohara et al., 2000, Lu et al., 2006a]. Usually, the end-exhale position is
used as the center of the GW, as highlighted in Fig. 1.12. A motion monitoring signal is used to
control beam extraction. While there is limited additional normal tissue irradiation, the treat-
ment time is prolonged due to frequent beam interruptions as shown in Fig. 1.12. Conventional
radiotherapy and passive beam shaping also employ gating to reduce the effects of motion on
treatment delivery.
Beam tracking is a method where the tumor is followed by the beam throughout different mo-
tion phases in real time. Similar to gating, beam tracking is not limited to active beam shaping.
It was even proposed originally for photons [Keall et al., 2001] and later implemented clinically
in x-ray radiosurgery in the robotic Cyberknife Synchrony system (Accuray Inc., Sunnyvale, Ca.,
USA) [Brown et al., 2007, Kilby et al., 2010]. Regardless of a radiation type, a fast beam de-
livery system is required for beam tracking. In contrast to photon radiotherapy, beam tracking
with particles need to pay special consideration to range changes. At GSI beam tracking system
has been implemented. The solution for fast longitudinal range changes was carried out by
two polymethyl methacrylate (PMMA) wedges close to the target, that are operated via a linear
step-motor [Saito et al., 2009], as shown in Fig. 1.13. The step-motor can change the relative
distance between the wedges and therefore introduces more or less material the beam travels
through and consequently changes the effective beam energy (range). The beam position is
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Figure 1.13.: Schematic presentation of GSI’s beam tracking system. Two PMMA wedges,
mounted on a linear step-motor, can change the energy of the beam traveling
through. The changes in the lateral direction are achieved via dipole scanner mag-
nets. For the longitudinal adaptation two PMMA wedges are mounted on a step
motors. The thickness of the two PMMAwedges that particle beam travels through
is regulated and hence changing its range. Figure taken from [Groezinger, 2004].
1.2.5 Treatment planning
The task of treatment planning is to determine machine parameters in order to deliver pre-
scribed dose to the target, while not violating the maximum allowed dose to critical organs, also
known as organs at risk (OARs) [Richter, 2012]. Treatment planning thus revolves around the
dose optimization process and it is highly dependent on the delivery type used for treatment.
The optimization problem for tumors can be written as:
min
x
∑
i

f (x , Ai)− Dpre
2
(1.14)
Here i is a CT voxel, function f is a dose deposition model, x intensity of the radiation beams,
A patient geometry and beam parameters and Dpre is the prescribed dose.
The basis of treatment planning is a computed tomography (CT) image, where the target vol-
ume and OARs are delineated by a physician. Additional imaging, such as magnetic resonance
(MRI) or positron emission tomography (PET), is often used as a supplement to CT for enhanced
contrast of the anatomical structures.
Target definition
The definition of the target volume is crucial, since it has to cover the whole tumor, prevent
further tumor spreading, while at the same time it should not be too big to spare normal tissue.
The International Commission on Radiation Units (ICRU) recommends the following defini-
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tions for volumes used in treatment planning, which will be used in this work, see Fig. 1.14
[ICRU, 1993a, ICRU, 1999].
Gross Tumor volume: The GTV is the gross palpable or visible/demonstrable extent and location of
malignant growth.
Clinical Target Volume: The CTV is a tissue volume that contains a demonstrable GTV and/or sub-
clinical microscopic malignant disease, which has to be eliminated. This volume thus has to
be treated adequately in order to achieve the aim of therapy, cure or palliation.
Planning Target Volume: The PTV is a geometrical concept, and it is defined to select an appro-
priate beam size and beam arrangements, taking into consideration the net effect of all the
possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed
in the CTV.
Internal Target Volume: This is the margin that must be added to the CTV to compensate for ex-
pected physio-logical movements and variations in size, shape, and position of the CTV during
therapy.
Organs at risk: Organs at risk (OAR) are normal tissues whose radiation sensitivity may signifi-
cantly influence treatment planning and/or prescribed dose.
Figure 1.14.: ICRU treatment planning volumes definitions. Figure taken from [Richter, 2012]
Further recommendations of the ICRU state that 100% of the PTV volume should receive
between 95% and 100% of the planned dose [ICRU, 1993a].
Treatment planning for scanned ion beams
A treatment planning system (TPS) for active ion beams shaping has to model the active beam
delivery system and the beam interactions with the tissue. Furthermore, for ions heavier than
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protons the biological effectiveness and fragmentation must be considered, which add addi-
tional complexity to the TPS. A TPS for beam scanning was developed at GSI, called TRiP98.
The basic concepts of TRiP98 will be presented here, further reading can be found elsewhere
[Krämer et al., 2000, Krämer and Scholz, 2000, Richter et al., 2013].
TRiP98 divides the PTV into iso-energy slices, which are further divided into raster points
in a defined order that the beam will follow. In the optimization step, a gradient-decent al-
gorithm iteratively optimizes particle number for each raster point, so that the optimal target
dose is achieved.The dose can either be physical or biological, using the LEM biological effec-
tiveness (see Section 1.2.2). Physical characteristic of the beam include lateral scattering as
proposed by Molière [Molière, 1948] and nuclear fragmentation that yield secondary particles.
The patient specific geometry and tissue inhomogeneities are accounted for using a transforma-
tion from CT HU to water-equivalent path length (WEPL) [Geiss et al., 1999, Jäkel et al., 2001,
Rietzel et al., 2007].
GSI’s 4D treatment planning system
As mentioned in section 1.2.4 tumor motion can cause severe dosimetric errors. To asses dose
deficiencies and to overcome them, TRiP98 was expanded to be able to calculate time-resolved
(4D) treatment plans. The new software was named TRiP4D and a detailed description is given
by Richter et al. [Richter et al., 2013].
A static CT is not sufficient for 4D treatment planning. Time-resolved CT scans (4D-CT)
therefore have to be used. 4D-CT consist of several quasi-stationary sections, called motion
phases. Data is recorded in each slice throughout the whole motion and is then sorted to the
appropriate motion phases, according to motion signal [Rietzel et al., 2005a].
Besides a 4D-CT, a vital part of 4D treatment planning is image registration. It provides
quantification of motion with deformation maps between different 4D-CT motion states. Image
registration principles are described in Section 1.2.5. The image registration is not included in
TRiP4D, so an external software must provide the necessary deformation maps.
The calculation of a 4D dose starts with the division of the treatment plan into sub-plans,
according to the motion phase it will irradiate. The number of sub-plans is the same as the
number of motion phases (or the number of motion phases in a gating window, if gating is used).
Afterwards the number of particles is calculated in each voxel of all of the motion phases used.
Finally, the particle number in each voxel is transformed with the deformation map obtained
from registration, to the reference phase, where the accumulated dose from summed particle
numbers is calculated (see Fig. 1.15). If a biological dose is calculated, then besides particle
numbers, the energy spectra is also accumulated, so that the RBE can be calculated according
to LEM for the total dose to each CT voxel.
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Figure 1.15.: Experimental validation of a TRiP4D dose calculation on film response. On images
a)-e) the individual dose deposition for the five motion states is showed. Image f)
shows accumulated 4D dose and image g) a homogeneous dose on a stationary
film. Figure taken from [Richter, 2012]
Image registration
Temporal changes in the patient anatomy are assessed with image registration. The registration
can be made between different imaging modalities (CT, MRI, PET), between scans from different
days or between different phases in a 4D scan (4D-CT, 4D-MRI, 4D ultra sound). It requires two
images: a fixed and a moving one. The result of the registration is a deformation map originating
from the moving and pointing to the fixed image. Registration can be written as:
x ′ = x + uri(x) (1.15)
Here, x and x ′ are points in states r and i, respectively and uri is a vector field representation
of the transformation map. uri can be used to assess the motion amplitude, propagate contours
and calculate the 4D dose. It is important to note that certain steps in 4D treatment planning
require also inverse registration, from state i to r [Richter, 2012]. If a deformation map is
applied to the moving image, the new image is called warped image and it should be as close to
the fixed image as possible. Fixed, moving and warped image are shown in Fig. 1.16.
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Treatment
The treatment for NSCLC can consist of surgery, chemotherapy, radiation therapy, or a combi-
nation of modalities. The treatment course depends on tumor type and stage and on patient
overall condition The typical treatment is surgery for stage I and II disease [Tsao, 2016]. Surgery
resection consist of either lobectomy or pneumonectomy, together with sampling lymph node or
even a complete lymph node dissection. Surgery will only be performed if NSCLC patients have
enough lung reserve after lobe or lung is removed. The 5-year survival rate for NSCLC patients
undergoing surgery is about 55 to 70% and 35-55% for stage I and II disease, respectively.
For unresectable stage III lung cancer the treatment consist of either chemotherapy or radia-
tion therapy or a combination of both. The median survival for patients with unresectable stage
IIIA disease is 10-14 months [Tsao, 2016]. For all treated stage IIIB disease the median survival
is 7-15 months [K. et al., 2005].
Rather than treating stage IV disease, palliation of symptoms is the goal. With chemotherapy,
targeted drugs and radiation therapy the tumor burden can be lessened and the quality of life
can be improved. The prognosis is poor, with a median survival of only 9 months and less then
25% of the patients survive the first year after the disease is diagnosed [Tsao, 2016]. A recent
phase II trial combined chemotherapy with stereotactic body radiation therapy and showed
promising results with 20 months overall survival [Iyengar et al., 2014].
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2.1 Introduction
Today most modern clinics regularly use different imaging techniques including CT, 4D-CT, cone-
beam CT, MRI and PET. A registration is needed to overlay different image acquisitions, such as
images taken at different days, between different imaging modalities or to quantify anatomical
changes in a time-resolved image acquisition, such as 4D-CT, 4D-MRI or 4D ultra sound. While
most commercial treatment planning software provide rigid registration between different im-
ages, deformable image registration (DIR) is currently rarely used. DIR can quantify anatom-
ical and biological variations better compared to rigid registration [Sarrut, 2006]. It opens
exciting new options in radiotherapy, such as 4D optimization [Trofimov et al., 2005], 4D dose
calculation [Flampouri et al., 2006] or contour propagation [Lu et al., 2006b]. 4D dose calcu-
lation has been well established for photons [Ong et al., 2016], protons [Paganetti et al., 2005]
and carbon-ions [Gemmel et al., 2011] and has received several experimental verifications
[Vinogradskiy et al., 2009, Perrin et al., 2016, Bert et al., 2012b].
A 4D dose calculation requires DIR for the deformation of the dose distributions in each
motion state to the reference state, where the dose from all motion states is accumulated. 4D
dose calculation requires accurate DIR at every voxel, since errors in DIR can significantly alter
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the 4D dose [Heath and Seuntjens, 2006]. Special consideration has to be paid to calculation of
biological 4D doses [Gemmel et al., 2011].
Contours can be propagated either with DIR [Lu et al., 2006c, Rietzel et al., 2005b] or with
deformable model driven techniques [McInerney and Terzopoulos, 1996], which uses a physical
model to iteratively match the contour to image features. In contrast to a 4D dose calculation,
contour propagation requires accurate DIR at the contour boundaries.
Besides radiotherapy, DIR is used also in other medical fields [Cleary and Peters, 2010,
Herrell et al., 2012, Nithiananthan et al., 2011, Naini et al., 2010]. Several different DIR algo-
rithms are available, such as B-spline [Rueckert et al., 1999], Demons [Thirion, 1998], linear
elastic finite element [Venugopal et al., 2005], optical flow [Zhong et al., 2007] or viscous fluid
[Christensen et al., 1996].
The DIR has a large degrees of freedom and as such is an ill-posed problem and hence prone
to errors. The errors can result in image misalignments or in physically impossible vector fields.
One of the reasons why DIR is not commonly used in commercial softwares is the lack of proper
DIR quality assurance (DIRQA), which is essential for implementation of DIR in the clinical
work-flow. While several different DIRQA methods exist, none of them are definitive and most
of them are time consuming. It is possible to evaluate DIR with deformable phantoms, where
the type and size of deformation is known [Kashani et al., 2007, Kirby et al., 2011]. However
this effort is prohibitive in the everyday clinical work flow. DIR validation can also be based
on landmark positions, specifically their location before and after registration. In absence of
externally planted markers, locating landmarks in the patient anatomy can be time-consuming
and it can be difficult to identify landmarks in low-contrast regions [Varadhan et al., 2013].
Another option is to compare delineated contours with the propagated ones using the dice
similarity coefficient [Varadhan et al., 2013] or Hausdorff distance [Huttenlocher et al., 1993].
While more efficient than landmark checks, these techniques require additional delineation and
do not address the region within the contour.
A set of tools was created to systematically handle DIR and DIRQA in the open-source software
3D Slicer. Tools were tested on a large data set to verify their validity.
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2.2 Implementation
2.2.1 3D Slicer
3D Slicer (Slicer) is a software platform for the analysis and visualization of medical images
[Slicer, 2016a, Fedorov et al., 2012]. Slicer is a free, open-source software (BSD-style license)
available on Windows, MacOSX and Linux operating systems. It comes with a vast variety of
tools, such as:
• Handling all commonly image formats, including DICOM, NRRD and MHA
• Visualization of voxel images, polygonal meshes and volume renderings
• Image registration (rigid and non-rigid) and display of vector fields
• Automatic image segmentation
• Analysis and visualization of diffusion tensor image data
• Device tracking for image-guided procedures
The source code of Slicer is written in C++ and with a Python wrapper to provide rapid,
iterative development. The graphical user interface is based on Qt. The visualization is based
on VTK [Vtk, 2016], a graphical library commonly used in scientific research.
Slicer is a research tool and as such allows implementation of new functionalities in the form
of extensions (modules). They can either be as external command-line programs, as scripts to
automate Slicer processes or as unique modules with new features.
2.2.2 Registration
Plastimatch [Shackleford et al., 2010] is a commonly used software for registration in medical
research. It is a free and open-source tool, available as a command-line executable program.
Plastimatch B-spline registration is also available in Slicer as part of the extension SlicerRT
[Pinter et al., 2012]. The integration of Plastimatch in Slicer brings the advantage of a graph-
ical user interface, offering a quick modification of parameters and visualization of the results.
However, automation is needed for a large number of registrations. For a complete 4D-CT regis-
tration there are 2(N −1) registrations required - from the reference phase to each of N motion
states of 4D-CT and vice versa, except for the reference phase itself. Typical 4D-CTs consist of
10 phases, therefore automated registration of a 4D-CT is necessary.
The automated DIR was achieved with a Python class to handle image locations, store DIR
parameters, perform DIR in the Plastimatch module, use correct naming conventions and store
all output files (vector fields and warped images). Details can be found in Appendix A.
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Registration nomenclature
To provide a clear and consistent description of methods used, an overview of the expressions
is given here.
• Reference image - the image that serves as a reference position in registration (image that
is being registered to).
• Moving image - the image that is matched to the reference image (image that is being
registered from).
• Warped image - the result of applying a transformation map from registration to the
moving image. It should be as close to the reference image as possible.
• True registration - the registration from the moving to the reference image. Similar,
everything connected to the true registration will use “true” (true vector field, true warped
image, true absolute difference, true Jacobian, etc.).
• Inverse registration - the registration from the reference to the moving image (opposite
or inverse of the true registration). As in the true registration, the term inverse can be used
for everything connected to it (inverse vector field, inverse warped image, inverse absolute
difference, inverse Jacobian, etc.).
In radiotherapy the true registration is used for dose propagation and consequential the 4D
Dose calculation, whereas with the inverse registration contours can be propagated from the
reference to the moving phase.
2.2.3 Registration quality tests
In order to provide visual and quantitative assessment of the registration quality a Deformable
Image Registration Quality Assurance or DIRQA module was created. It provides image
checks (inverse color, checkerboard, absolute difference, flicker, movie and landmark distances)
and vector checks (Jacobian and inverse consistency error). The reference and warped image,
true and inverse vector are used as inputs for the DIRQA module. Additionally, landmarks and
a region of interest (ROI) can also be used as an input.
Tests can be divided into two groups: qualitative (inverse color, checkerboard, flicker, movie)
and quantitative (absolute difference, landmark distances, Jacobian and inverse consistency
error) tests. Absolute difference, Jacobian and inverse consistency error tests were build using
tools from the ITK library [Yoo et al., 2002].
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2.3 Verification
Several tools to perform DIR and DIRQA were created. To prove their functionalities, we have
tested them on two sets of an actual clinical data. First were the lung 4D-CT patient data from
the Champalimaud Center for the Unknown, Lisbon (Portugal). The 4D-CTs were used in the
treatment planning studies, presented in Chapters 3 and 4. DIR resulting from 4D-CTs played an
essential in these studies, since they were used in contour propagation to estimate and mitigate
tumor motion. In addition, DIR was also used in 4D dose calculation.
The second set of data were pig cardiac 4D-CTs. They were also used in treatment planning as
a part of an animal study, conducted at GSI. 4D-CT DIR was also used for contour propagation
and 4D dose calulation. However, the treatment plans were than actually used for the animal
irradiation. It was therefore necessary not only to obtain DIR, but also to ensure its quality.
The DIRs were calculated as explained in Section 2.2.2. Afterwards absolute difference, Jaco-
bian and ICE were calculated on resulting DIR as part of the the DIRQA.
2.3.1 Lung 4D-CT patient data
The effects of interplay between tumor motion and active beam scanning can drastically change
the dose distribution for PT. It is therefore necessary to estimate tumor motion and employ
designated motion mitigation techniques.
Chapters 3 and 4 present studies on simulating active scanning carbon ion treatment for non-
small cell lung cancer patients. The studies included data for 23 lung cancer patients. In order to
calculate realistic treatment plans, 4D-CT scans were used in studies. All 4D-CT were registered
to estimate and mitigate tumor motion and to calculate 4D doses. To ensure the DIR quality,
DIRQA was performed on all DIRs.
Materials and Methods
In total, 23 lung cancer patients were studied. For each patient, a time-resolved CT (4D-CT) was
acquired, consisting of 10 motion states (0 - 9) with 1 mm pixel and 1-2 mm slice spacing. They
were acquired with either a Philips Brilliance BigBore 16-slice (Philips Healthcare, Eindhoven,
Netherlands) or a Philips Gemini PET-CT 16-slice scanner. State 0 and 5 correspond to the
end-inhale and end-exhale breathing state, respectively. State 0 was chosen as a reference state.
True and inverse DIRs were computed for each patient between each state and the reference
state. Each 4D-CT required 18 DIRs, leading to 414 DIRs in total.
The B-Spline Plastimatch module in Slicer was used for DIR (see Section 2.2.2). DIRs were
done in two stages with details given in Table 2.1.
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Table 2.1.: Parameters used for B-Spline Plastimatch DIR. A mean squared error metric was used.
Details for each parameter can be found in [Plastimatch, 2016].
Parameter Stage 1 Stage 2
Resolution 4,4,2 1,1,1
Grid size 50 15
Regularization lambda 0.005 0.005
Iterations 200 100
A box-shaped ROI around the patient body was created with a Slicer build-in function. The
ROI was employed in calculation of absolute difference, Jacobian and ICE.
Default, true and inverse absolute difference were calculated. In total 621 absolute differences
were calculated. All images were down-sampled by a factor of 2 before calculation of absolute
difference to save computer time. Similarly, 414 vector fields were down-sampled by a factor
of 2 before calculating Jacobian and ICE. Jacobian and ICE checks were calculated on all vector
fields. Additionally, vector field magnitudes were analyzed for mean, standard deviation (STD)
and maximum (max) values. Paired t-tests were performed to compare mean, STD and max
of true and inverse vector field magnitudes. A p-value < 0.05 was considered significant. A
Pearson’s r coefficient was used to determine linear fit quality.
For each patient it took around 20 min for all 18 DIRs and around 30 min for complete DIRQA
on the 9 motion states. A cluster of different Linux computers, each with 8 CPU and 32 GB RAM
were used for DIR and DIRQA.
DIR was used in treatment planning, specifically in contour propagation and 4D dose calcu-
lation. The areas with poor DIR were investigated and distance between DIR errors and target
contour was measured. If the target and the beam path was more than 5 cm away from DIR
errors, DIR was not repeated.
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Discussion
Nine states of 4D-CTs were registered to a 4D-CT reference state for 23 lung cancer patients,
producing 414 true and inverse vector fields. All 414 DIR underwent a DIRQA consisting of
vector field magnitudes, absolute difference, Jacobian and ICE.
Vector field magnitudes confirm previously published data that the biggest motion for lungs is
in superior-inferior direction [Seppenwoolde et al., 2002, Britton et al., 2007, Liu et al., 2007].
The mean vector field magnitude is small (in submilimeter range), because the ROI included
the whole patient body, not just the lungs where most of the motion occurs. Vectors and inverse
vectors are similar, which was expected.
There was a high correlation (Pearson’s r = 0.87) between absolute difference before and after
DIR. The slope of the linear fit suggests that the B-Spline DIR on average halves the absolute dif-
ference. There are several outliers from the linear fit for default absolute difference bigger than
50 HU, however no DIR errors could be found upon visual inspection for this outliers. All ab-
solute differences after the DIR are smaller then before, which is a necessary condition in order
for DIR to be considered successful. Apart from smaller absolute difference after DIR, nothing
could be deducted about the DIR quality from the absolute difference. The absolute difference
is limited by the image noise, which will always be present in a CT scan [Polacin et al., 1992].
It would be interesting to study the correlation between image noise, absolute difference and
consequential DIR quality.
Due to small mean vector field magnitudes, average values for true and inverse Jacobian
were 1±0.05, which indicates that most of the patient body does not change during the 4D-CT
scan. However, patients expansions and contractions can be seen on maximum and minimum
Jacobian, with average values around 1.50 and 0.65 respectively.
ICE Mean and STD values were in submilimeter range, due to the correlation between vector
field and ICE (see Eq. 2.2). The maximum ICE (2.3 cm) was observed in a patient with an
artifact present in state 2 of the 4D-CT, as shown in Fig. 2.9.
Large vector field magnitudes will produce more errors in DIR as shown in Fig 2.9. Linear fits
were used to estimate the increase (decrease) of the Jacobian and ICE. As a rough DIRQA check,
ICE should always be smaller than the maximum vector field magnitude. To confirm this, all
cases above the dashed line in Fig 2.9c were investigated. For all areas of poor DIR were found.
An extreme case (highlighted in Fig. 2.9a-c) had a large image artifact present in states 2 and 3
(state 3 with ICE is shown in Fig. 2.9d) leading to large inconsistencies in DIR. The effect of DIR
inconsistency on contour propagation can be seen in Fig. 2.11, where lungs and liver contour
were propagated using DIR. The propagated contours clearly differ from the image features.
The 4D-CT DIRs investigated here were used in particle therapy treatment planning. All areas
that were found to have a poor DIR, were so far away from the target, that contour propagation
or 4D dose calculation were not affected. Hence a repetition of DIR was not necessary. The
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2.3.2 Pig heart 4D-CT data
Atrial fibrillation is the most common type of cardiac arrhythmia, causing a quivering motion
of the atrial small heart chamber. Although atrial fibrillation directly is not a life threat-
ening condition, it worsens the patient’s quality of life and increases the risk of a stroke
[Benjamin et al., 1998]. A common method for treating the atrial fibrillation is a catheter abla-
tion [January et al., 2014]. The success rate of a catheter ablation is still limited and can lead
to major complications or even death of a patient [Cappato et al., 2005, Cappato et al., 2010].
As an alternative treatment, carbon-ion therapy was proposed [Bert et al., 2012a] and later
the feasibility was shown on a beating heart experimentally [Lehmann et al., 2015]. In 2014 a
pilot experiment was performed at GSI using large animal model (pigs) and scanned carbon-ion
to verify the treatment in vivo [Graeff et al., 2015].
To estimate and compensate motion of the heart during irradiation DIR of 4D-CT data was re-
quired. Furthermore, because of the actual irradiation of pigs a DIR quality had to be estimated
and repeated, if necessary.
Materials and Methods
Pig irradiation experiment
DIR and DIRQA procedures will be given here, while a detailed description of the whole pig
irradiation experiment can be found elsewhere [Graeff et al., 2015]. Cardiac gated contrast-
enhanced CT scans (cardiac 4D-CT) were made on 15 pigs with a multidetector 64 row Siemens
Somatom Definition Flash scanner (Siemens Healthcare, Forchheim, Germany) with 1 mm voxel
and 1 mm slice spacing. There was no breathing motion present, since a breath-hold technique
was used. Cardiac motion was based on electrocardiography (ECG) and was divided into 10
sequential states (0-9). Eight pigs had a pacemaker implanted, because the irradiation was
planned to damage the atrioventricular (AV) node and a pacemaker should compensate for
that. Pigs are therefore divided into two groups, with pacemaker (PM), n= 8, and without one
(noPM), n = 7. The 4D-CT were acquired between 2nd and 16th July and the irradiation took
place between 21st and 24th July.
After the CT acquisition, DIR on cardiac 4D-CT was calculated using the B-Spline Plastimatch
module in Slicer (see Section 2.2.2). Details on parameters used for DIR can be found in Ta-
ble 2.3. State 0 was chosen as a reference state. State 3 corresponds to a maximum heart
contraction with likely the biggest motion. All other states were registered to the the reference
state with an inverse registration as well. A checklist was made to follow DIR and DIRQA for
quality assurance. An example of a filled-out checklist is shown in Fig. 2.12a.
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Based on lung patient DIR and because of the time constraints in the study workflow, DIRQA
was made only on DIR from state 5. DIRQA consisted of default and true absolute differences,
true Jacobian and ICE. DIRQA results were stored in a text file (example shown in Fig. 2.12b)
and users checked if the values did not exceed expected ones: Mean absolute difference should
be smaller than 1; mean Jacobian should be 1; mean ICE should be smaller than 2 mm. A
box-shaped ROI was created in Slicer to encompass the pig body and then used in all DIRQA
checks.
After a successful DIR and DIRQA, vector fields were used for treatment planning and the
resulting plans were used in the pig irradiation experiment.
Around 20 minutes were needed for each pig DIR and additional 20 minutes for pig DIRQA.
Calculations were done on a cluster of Linux computers, each with 8 CPU cores and 32 GB RAM.
Table 2.3.: Parameters used for Plastimatch registration. A mean squared error metric was used.
Details for each parameter can be found here [Plastimatch, 2016].
Parameter Stage 1 Stage 2
Resolution 4,4,2 2,2,1
Grid size 50 15
Regularization lambda 0.005 0.005
Iterations 200 100
Post-experiment analysis
After the completion of the animal study, a more detailed DIRQA was made, with all motion
states included in DIRQA. In addition to the original checks explained in the previous section,
vector field magnitudes were analyzed, the inverse absolute difference and the Jacobian were
calculated. Paired t-tests were used to test statistical significance for vector field magnitudes
between the true and inverse vector fields and PM and noPM groups. For linear fit quality
estimation, a Pearson’s r coefficient was used.
61

Figure 2.13.: (a) Mean true and inverse absolute difference plotted against mean default abso-
lute difference. The solid line shows a linear fit, with parameters written in the top
left corner. Dashed line shows y(x) = x . (b) Box plots of mean default absolute
difference distribution across nine 4D-CT states. Boxes represent 25-75%, whiskers
10-90% of data. The median is shown with a solid line, the mean is represented
with squares and outliers with crosses.
Results
An example of a pig cardiac 4D-CT DIR is shown in Fig. 2.14. One DIRQA during the animal
study showed higher mean true absolute difference than mean default absolute difference. The
registration was therefore repeated with three stages instead of 2. The third stage had 100
iterations with resolution size “1, 1, 1“ and grid size ”10“. All other DIRQA checks were positive.
A post-experiment statistical analysis on vector field magnitudes is shown in Table 2.4. No
statistical difference was observed between the true and the inverse vector fields. However,
significant differences were observed between the vector field magnitudes of PM and noPM
groups. The contributions to vector field magnitudes from three axis were equal.
Table 2.4.: Data for vector magnitudes. Values are presented as mean (range).
PM noPM
True vector field Inverse vector field True vector field Inverse vector field
Mean 0.08 (0.03 - 0.16) 0.08 (0.03 - 0.14) 0.07 (0.0 - 0.18) 0.06 (0.0 - 0.17)
STD 0.4 (0.09 - 0.78) 0.36 (0.08 - 0.68) 0.3 (0.05 - 0.77) 0.28 (0.04 - 0.71)
Max 8.24 (1.6 - 17.33) 7.98 (0.7 - 17.76) 5.9 (0.97 - 15.91) 5.38 (1.08 - 12.42)
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Discussion
All 15 pig 4D-CTs have been registered, which resulted in 270 DIRs. DIRQA was performed in
two steps - a smaller DIRQA during animal study on one state and a complete DIRQA on all
4D-CT states afterwards.
Mean vector field magnitudes were small (approx. 0.1 mm), since pigs were in a breath-hold
position and the only motion was the heartbeat. Despite the small mean vector magnitudes
it was still enough to observe statistical difference between PM and noPM. Consequently, the
difference between the two groups is consistent throughout the DIRQA.
DIR did well in terms of lowering the absolute difference. There was a strong correlation
between default versus true and inverse absolute difference. The slope of the linear fit on
Fig. 2.13 has the same value than the slope from lung 4D-CT (see Fig. 2.8), showing the ef-
fectiveness of the B-Spline algorithm. The distribution of the default absolute difference across
different states is smaller than in lung 4D-CT (10 HU compared to 35 HU), due to the fact less
motion was present in a pig cardiac 4D-CT. The shape of default absolute difference distribution
persist then in the Jacobian and ICE distributions as well.
A good result in absolute difference does not necessary mean a good DIR, as can be seen from
Jacobian and ICE checks. The mean Jacobian and ICE were 1 and 0, respectively, since the vector
fields were small on average. However there were large deviations present in Jacobian and ICE.
Most notably, there were a few cases of negative minimum Jacobian which would suggest organ
folding. Since organ folding does not occur during a heart beat, negative minimum Jacobian
points to inconsistencies in DIR.
The large deviations in Jacobian and ICE can in part be explained with large maximum vector
field values, as shown in Fig. 2.16. All linear fits have a good correlation, with no difference
between PM and noPM in the quality of the fits. The actual linear fit parameters, however,
further show the inconsistencies in DIR. The clearest example of inconsistencies in DIR is with a
linear fit from maximum ICE PM, which lies above the function y(x) = x . This means that there
were points further away from the starting point after the true and inverse transformation, then
just after true transformation. The linear fit for noPM maximum ICE showed better results in
this terms, since it lied below the y(x) = x function.
During the animal study only one DIR was repeated because of DIRQA. It was shown in post-
experiment analysis, that most of the DIRs should be repeated, pointing out flaws in initial
DIRQA procedure. Mainly, DIRQA should be made on all DIR and not just on one state, since
DIRQA from one DIR does not guarantee the quality of the other DIRs from the same 4D-CT.
Each DIR is performed individually and should be treated as such. Furthermore, instead of
mean Jacobian and ICE, maximum and minimum should be investigated, because it points to
the worst part of the DIR.
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2.4 Summary and Discussion
Tools to perform DIR and DIRQA have been presented in this chapter. Modules were written for
an open-source software Slicer that can handle large DIR problems, such as registering whole
4D-CTs. In addition to DIR, the modules can also provide quantitative information on DIR
quality. The main objective of this work was to provide a systematic approach for DIR and to
give parameters on DIRQA that can estimate the quality of DIR. A first analysis of DIRQA checks
was done on a large DIR database - 684 DIR were checked in total.
Most of the work was based on Slicer, which is a well-established software in medi-
cal research. To date, there are more than 500 publications that have used Slicer in
their research [Slicer, 2016b], with topic ranging from teaching [Pujol et al., 2016], disease
staging [Liu et al., 2015, Liu et al., 2016a], motion tracking [Behringer et al., 2015] to image
reconstruction [Meyer et al., 2015], image registration [Li et al., 2015b, Fedorov et al., 2015,
Li et al., 2015a] and others. Slicer offers ample functionalities and is especially suited for re-
search, since it can be modified to specific needs. However, it is important to stress that Slicer is
not a medical product and as such can not be used in clinic. Additionally, Slicer can sometimes
be unstable with unexpected crashes. It is constantly under development and more and more
errors are fixed with each new release. New releases also bring new functionalities, but there
can be problems with backtrack compatibility.
Results shown in this chapter were obtained with the B-Spline DIR algorithm. Several other
algorithms exist, demons most commonly used alongside B-Spline [Thirion, 1998]. Varadhan et
al. compared B-Spline and demons DIR for lung cases [Varadhan et al., 2013] and showed that
B-Spline is superior to demons, especially if there is a difference in contrast between the images.
They used a mutual information metric, to account for differences in contrast. Images used in
this chapter were either all without (lung 4D-CTs) or all with (animal study 4D-CTs) contrast
agent, therefore no difference in contrast between images was present and mutual metric could
not be used.
A designated module was written for DIRQA. The main advantage of the DIRQA module is
that all different techniques are gathered in a single place and can be used on a specific case.
The ease of use is also essential, for DIRQA to find its way into clinical work flow. A test of using
DIRQA in potential clinical work flow was done at GSI during the animal study, where differ-
ent users operated with both DIR and DIRQA modules. The experiment was carried out under
time pressure, since there was a scheduled beam time. 4D-CTs were acquired approximately two
weeks before the scheduled irradiation. During this two weeks contour delineation, DIR, DIRQA,
treatment planing and treatment planning QA had to be done [Graeff et al., 2015]. There were
already propositions for frameworks for DIRQA in clinical work flow [Varadhan et al., 2013],
however none were tested in an actual clinical environment. An animal study can not be di-
rectly compared to an actual clinic, however the number of pigs studied was high (15) and
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the study was under time constraint, which simulate some of the pressures present in clinical
environment.
The techniques used in DIRQA were divided into qualitative (inverse color, checkerboard) and
quantitative (absolute difference, Jacobian and ICE). While the quantitative can be used to pin-
point errors in DIR, the qualitative can be used to actually locate the error as shown in Fig. 2.9d.
The location and size of DIR error also determines if a repetition of DIR is necessary. All three
quantitative checks have been used in literature as a possible DIRQA [Varadhan et al., 2013,
Leow et al., 2007, Christensen and Johnson, 2001, Bender and Tomé, 2009]. They all share the
same flaw, however, that they are a necessary but not sufficient condition for a successful DIR.
One common DIRQA check in literature that our module is currently missing, is comparison
of anatomical correspondence - comparison between reference, moving and warped contours.
Ideally the warped and the reference contour should be the same. Two metrics are usually
used in contour comparison - dice similarity coefficient [Varadhan et al., 2013] and Hausdorff
distance [Huttenlocher et al., 1993]. Slicer already has functionalities for both contour compar-
ison checks, so they could be used. The biggest disadvantage of the anatomical correspondence
check is that the contour delineation is required in both, the reference and moving phase, which
is scarcely done by physicians, since it takes too much time. Additionally, the anatomical corre-
spondence check does not judge the vector field quality inside contour. The lack of contours in
both reference and moving phase was the reason the anatomical correspondence check was not
used.
Studies on DIRQA so far have focused on a small number of DIR cases, whether
it is phantom [Mutic et al., 2001, Moore et al., 2004] or patient studies [Wu et al., 2008,
Varadhan et al., 2013]. With a small number of DIRs, it is possible to thoroughly examine
each DIR and hence understand DIRQA. In this work a different approach was used. Rather
than examining each DIR individually, a large dataset was analyzed and common traits for DIR
were found. Due to differences in anatomical sites, DIRQA parameters have to be found for each
anatomical site individually, since they can deviate significantly, as seen by two different cases
presented here. However, three checks are independent on anatomical site: mean true and ab-
solute difference should be lower than default absolute difference, Jacobian should be positive
and ICE should be smaller than maximum vector field magnitudes. If any of these checks fails,
DIR needs to be investigated and, if necessary, repeated.
DIR of a lung 4D-CT can be considered relatively easy, since the contrast between lungs and
other tissue is high. This is confirmed by a mean value of 1 for the Jacobian and mean ICE
smaller than 1 mm. The maximum and minimum Jacobian and ICE are more interesting, since
they show DIR inconsistencies. All ICE values bigger than maximum vector field magnitudes
were found to originate from areas with a poor DIR. An effect of a poor DIR can be seen in
Fig. 2.11, where the propagated liver and lung contour do not match features on the image.
An image artifact was the reason for the poor DIR. After investigation of poor DIR location and
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size, it was decided, that DIR does not require repetition, due to large distance between poor
DIR and the tumor.
If the DIR of lung 4D-CT was considered relatively easy, opposite holds true for DIR of ani-
mal study 4D-CT. The motion of the heart during a heartbeat is complex, with muscles relaxing
and contracting in different directions [Seeley et al., 2007]. Furthermore, the volume of blood
shifts from one ventricle to the other. In the case of a cardiac 4D-CT, blood carried a contrast
agent and blood distribution in heart was changing during a heartbeat. Therefore the HU dis-
tribution varied drastically in different cardiac 4D-CT states. Additionally, it is well established
that pacemakers cause several complications in a CT scan [Mak and Truong, 2012]. This was
confirmed by the differences observed between PM and noPM. The clearest example is the PM
linear fit of the maximum ICE in Fig. 2.16, which is above y(x) = x . For noPM the linear fit is
below y(x) = x , however the slope has still a value of 0.77, compared to 0.38 of a lung 4D-CT
fit. Inconsistencies in DIR were further supported by negative minimum Jacobian, which were
found for both, PM and noPM groups. Negative minimum Jacobian and large ICE values are
clear indicators, that DIR in heart can not be accepted for heart treatment planning and needs to
be repeated. An effect of DIR on actual irradiation also has to be examined. The DIR of cardiac
4D-CT is currently under careful investigation and several different solutions, such as artifact
removal and different registration parameters are being tested.
In the future, the DIRQA module should undergo further testing. In addition to checking
DIRQA on different anatomical sites and between different modalities, it should be investigated
how good DIRQA is at spotting inconsistencies in DIR, i.e. what is the number of false nega-
tives. Furthermore, with more data analyzed, the parameters in DIRQA checks should get more
precise, so outliers could be more easily spotted.
Based on the findings presented here, several new features could improve the DIRQA module.
Instead of the mean, STD, maximum and minimum values, histograms could be displayed for
quantitative tests. Furthermore, histograms could be displayed for a specific contour, such as
the tumor, which would give a direct indication of DIR quality effect on treatment planning.
Additionally, the module should automatically show the location of maximum and minimum
Jacobian and maximum ICE. The worst part of DIR could be than immediately recognized and
appropriate response could be formed.
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3 Comparison of Photons versus Carbon
Ions in Single Fraction Therapy of Lung
Cancer
3.1 Introduction
Lung cancer is one of the leading medical problems worldwide with approximately 1.4 mil-
lion deaths per year [Siegel et al., 2014]. Surgery is usually the first choice in treating local-
ized non-small cell lung cancer (NSCLC). However, in recent years stereotactic body-radiation
therapy with photons (SBRT) showed very promising results, with high local control-rates
of NSCLC [Baumann et al., 2009, Fakiris et al., 2009, Grutters et al., 2010, Ricardi et al., 2010,
Timmerman et al., 2010, Greco et al., 2011].
Scanned particle therapy can produce sharp dose gradients with a finite range of the
beam and can thus provide higher normal tissue sparing. This reduces both side effects as
well as the risk of secondary cancer [Newhauser and Durante, 2011]. Treatment of lung tu-
mors with particles is still challenging due to interplay and radiological path length changes
[Bert and Durante, 2011]. The latter can be substantial when dense tissue (e.g. the solid tumor
mass) is replaced with low-density tissue (lung) due to motion.
Grutters et al. have performed a meta-analysis on comparison between photon, proton and
carbon ions in treating NSCLC [Grutters et al., 2010]. They found similar 5-year survival rates
for SBRT, protons and carbon-ions (around 40%). However, the number of patients treated with
particle therapy was low and they advise caution when interpreting the data. Also different
fractionation schemes were used in the comparison. A more recent review was published by
Kamada et al. [Kamada et al., 2016] where they reported a high 3-year survival rate for single-
fraction carbon-ions (76.9%), with no late treatment-related adverse effects. In comparison,
SBRT had 55.8% 3-year survival rate, with 10 - 27% of patients exhibiting grade 3 treatment-
related adverse effects [Timmerman et al., 2010]. It is important to note that all of these studies
used passive beam scattering, avoiding the problem of interplay between organ motion and
scanning beam motion. On the other hand, active beam scanning can provide even better dose
shaping which becomes essential in high dose single fractionation regimes. The effects of motion
and motion mitigation techniques on scanned carbon ion dose distribution therefore need to be
considered in a fair comparison of photons and carbon ions.
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To evaluate potential advantages of active scanning with carbon ions (PT), an in silico com-
parison of simulated PT plans to SBRT plans actually delivered was conducted. Target coverage
and a wide range of OAR doses were assessed both with and without simulated motion on
time-resolved computed tomographies (4D-CTs).
3.2 Materials and methods
3.2.1 Patient data
The study included 19 patients with in total 26 lesions that were actually treated with SBRT
at the Champalimaud Centre for the Unknown, Lisbon (Portugal). The lesion size was 2.9 cm3
(median, 25-75% 1.4 - 9.7) and peak-to-peak motion was 3.1 mm (1.6 - 5.6). Three patients
had two targets, one had five and the rest one. 13 lesions were right-sided, 12 were left-sided
and one was located in right cardiophrenic space. An overview of tumor characteristics can
be found in Table 3.1. Two CTs were available for all patients. A planning CT was used for
OAR delineation and SBRT planning. Target motion was estimated on a 4D-CT, consisting of 10
phases (0% - 90%). Clinical target volumes (CTV) were delineated using a registered positron
emission tomography (PET) scan.
The planning objectives were that 99% of planning target volume (PTV) must receive at least
24 Gy (D99% ≥ 24 Gy) in a single fraction, while all OAR constraints as defined in the AAPM
task group 101 report on stereotactic radiotherapy had to be respected [Benedict et al., 2010].
Details on OAR constraints can be found in Table B.1.
3.2.2 Planning target volume definition
To account for range changes relevant for particles only, different PTV definitions were used for
SBRT and PT, as shown in Fig. 3.1. Within this chapter they will be named PTVSBRT and PTVPT
for SBRT and PT, respectively. In SBRT, the responsible clinician determined the maximum
breathing motion of the CTV from the 4D-CT, hence creating an ITV. This ITV plus an additional
3 mm for setup uncertainty yielded the PTVSBRT .
PTVPT was constructed following principles from Graeff et al [Graeff et al., 2012]. Each beam
has a unique PTVPT . For setup uncertainty margins of 3 mm laterally and 1 mm in beam’s eye
view (BEV) were used on the CTV. Afterwards a water-equivalent path length ITV (WEPL-ITV)
was build, using transformation maps from the B-Spline deformable registration of the 4D-
CT data [Shackleford et al., 2010]. Additional 2 mm + 2% proximal and distal margins were
added in BEV to account for uncertainty from Hounsfield units to water equivalent path length
conversion. If the target overlapped with an OAR (e.g. small airways) then OAR plus a margin
of 2-5 mm was subtracted from PTVSBRT or PTVPT .
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Table 3.1.: Lesion characteristics, with lesion locations, stages, peak-to-peak motions and vol-
umes of corresponding CTV, PTVSBRT and PTVPT . Abberevations for lesion location
are: RSL, right superior lung; IRL, inferior right lung; LSL, left superior lung; ILL, infe-
rior left lung; RCS, right cardiophrenic space.
Volume (cm3)
Patient Lesion
Location Stage
Peak-to-peak
CTV PTVSBRT PTVPTNumber Number motion [mm]
1 1 LSL IIa 4.8 35.9 100 179
2 2 LSL Ia 3.1 1.6 7.7 40.6
3 3 IRL IV 12 2.3 11.6 32
3 4 RSL Ia 0.5 6.9 25.2 38
4 5 ILL IV 4.4 2.5 15 20.5
5 6 ILL IV 7.5 1.4 7.7 26.5
6 7 RSL IV 3.9 16 40 72.5
7 8 ILL IV 0.6 139 261 255
8 9 LSL IV 2 9.2 35 46.5
8 10 IRL IV 3.4 10.2 38 45.5
9 11 ILL IV 2.8 14.4 46.4 57.2
9 12 ILL IV 5.8 3.8 17.4 23.4
10 13 RSL IV 0.8 4.3 17.7 26.3
10 14 LSL IV 3.4 2.7 14.5 23.1
10 15 RSL IV 2.1 3.1 15.4 33.5
10 16 LSL IV 0.5 0.5 5.4 6.7
10 17 ILL IV 7.8 0.8 6.1 23.5
11 18 LSL IV 0.1 1.7 15 23.5
12 19 IRL IIIb 11.4 27 137 118.5
13 20 RSL Ia 2.2 1.7 10 23.4
14 21 RSL IV 0.2 0.9 3.2 14.9
15 22 RSL IV 2.2 3.9 22.1 27.5
16 23 LSL IV 3.1 9.8 28 51
17 24 RSL IV 8.1 0.6 3.3 4.1
18 25 LSL IV 1.4 0.8 5.9 10
19 26 RCS IV 11.8 0.4 6.6 8.6
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3.2.4 Carbon-ion treatment planning
For PT, state of the art 4D treatment planning software TRiP98 was used [Richter et al., 2013]. A
single field uniform dose plan (SFUD) was optimized on the PTVPT in the end-inhale reference
phase of the 4D-CT. Most targets (n = 20) were planned with two fields. For the remaining
targets, one (n = 1), three (n = 3) or four (n = 2) fields were used due to proximity of OARs.
A regular grid of beam spots with a spacing of 2 mm, a beam spot full width at half maximum
(FWHM) size of approximately 6 mm and a 3 mm ripple filter were used. To compensate for
short particle ranges in lung tissue, a bolus of 80 mm water-equivalent thickness was added.
The relative biological effectiveness (RBE) following the local effect model (LEM) IV
[Elsaesser et al., 2010]. For a conservative estimation, an alpha-beta ratio of 6 Gy and 2 Gy
were used for target and OARs, respectively. This led to an RBE of approximately 1.1 in target
tissue and approximately 1.1 to 3 in OARs. Dose was calculated on end-inhale (3D-Dose0%) and
end-exhale (3D-Dose50%) phases. 4D dose delivery was simulated as described by Richter et al
[Richter et al., 2014]. Two different breathing periods (3.6 and 5 s) and two different starting
phases (0° and 90°) were used. Simulations without motion compensation (4D-Doseinterpla y)
and with slice-by-slice raster rescanning were performed (4D-Doserescan). Five rescans were
used for the majority of targets (n=24), whereas 20 rescans were used for targets where the
interplay effects were too big to achieve a satisfactory target coverage (n = 2; lesions 3 and 18
in Table 3.1).
3.2.5 Dose metrics and analysis
For comparison between SBRT and PT the following dose metrics were used - for the target the
minimum dose in 99% of the volume (D99%), which should be higher than 24 Gy; for OARs, the
maximum point dose (DMax) and the mean dose (DMean). Additionally, the volume receiving
20% of the planned dose (V20%) was used to assess differences in lung doses. In all cases,
absorbed dose in Gy for SBRT was compared to biologically-equivalent dose in Gy(RBE) for PT.
Paired t-tests were performed to compare the dose metrics and for post-hoc exploratory anal-
ysis between groups a two-sided t-test with Welch correction for different variances was carried
out. A p-value < 0.05 was considered significant. Dose differences are always reported such
that higher dose levels for SBRT result in positive values.
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Table 3.2.: Dose metrics for OARs. First value at each organ is from SDRT and the second from
4D-rescan. All values are shown as median and 25-75% in brackets.
DMax (Gy) DMean (Gy)
OAR Photon Carbon Photon Carbon
Heart 6.0 (0.3 - 11.6) 0 (0 - 8.8) 1.3 (0.1 - 2.2) 0 (0 - 0.5)
Spinal Cord 5.5 (3.3 - 8.5) 0 (0 - 0.5) 0.7 (0.3 - 1.2) 0 (0 - 0)
Smaller Airways 13.0 (9.8 - 17.1) 10.3 (3.3 - 19.1) 2.8 (1.5 - 5.8) 0.5 (0 - 2.6)
Esophagus 5.8 (3.9 - 8.4) 0 (0 - 0.3) 1.1 (0.6 - 1.5) 0 (0 - 0)
Trachea 3.9 (1.8 - 5.4) 0 (0 - 0) 1 (0.3 - 1.3) 0 (0 - 0)
Aorta 8.0 (5.1 - 21.9) 3.9 (0 - 18.1) 1.4 (0.7 - 1.6) 0.1 (0 - 0.4)
Ipsilateral Lung 26.3 (26.0 - 26.5) 26.3 (25.8 - 26.5) 1.9 (1.5 - 3.0) 1.9 (1.4 - 2.5)
Contralateral Lung 5.0 (3.5 - 9.6) 0 (0 - 0.9) 0.4 (0.2 - 0.6) 0 (0 - 0)
3.3.3 Dependence on CTV Size
Significant differences were observed between patients with a single CTV smaller (n = 8) or
larger (n = 7) than 2.5 cm3 for DMax and DMean, see Fig. 3.4. For patients with a smaller
CTV, the dosimetric advantage over SBRT was on average 0.9 Gy and 0.5 Gy lower for DMax
and DMean, respectively. This was associated with PTVPT definition - the average volume ratio
between PTVPT and PTVSBRT was 2.9 (1.6 - 4.0) and 1.5 (1.3 - 1.8), for patients with CTV < 2.5
cm3 and CTV > 2.5 cm3, respectively.
The 4 patients with multiple lesions were excluded from this comparison. The DMax and
DMean difference were on average higher in these patients, but the number of patients was too
low for statistical analysis.
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Figure 3.4.: Box plots of average OARs max point dose (DMax ) and mean dose difference be-
tween SBRT and PT for patients with single CTV smaller (n = 9) or bigger (n = 6)
than 2.5 cm3. Boxes represent 25% - 75%, outliers are shown as whiskers and me-
dian is shown with solid lines. Values for patients with multiple lesions are shown
with circle symbols.
3.4 Summary and Discussion
This is the first in silico trial directly comparing clinically valid SBRT plans to scanned carbon
ion plans using state of the art 4D dose calculation and motion mitigation methods for NSCLC
patients. Our study found that PT deposited less dose to OARs compared to SBRT. Therefore PT
might be considered as an alternative treatment option to SBRT. The finite range of the beam
permits a small number of fields and thus a narrow entry channel, so that critical OARs such
as spinal cord, heart, esophagus, and the contralateral lung could be effectively spared using
PT, with typically low or even zero dose. PT could be thus highly beneficial to patients with
impaired contralateral lung function, because PT deposited no dose in the contralateral lung
in 12 patients, while SBRT irradiated the contralateral lung in all patients. Being an intensity-
modulated arc therapy, SBRT had an advantage in some patients where the smaller airways
were in a close proximity to CTV; SBRT could shape the dose distribution to reduce dose to the
smaller airways, compensating PT’s advantageous physical dose characteristics.
Further increase in OAR sparing could be achieved by using intensity modulated particle
therapy (IMPT) instead of SFUD. While IMPT could lead to less dose in the OARs, it would
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make the plans less robust against setup errors due to additional dose gradients between the
fields. These gradients can be controlled by employing robust optimization to account for range,
motion and setup uncertainties, which we will implement in a future 4D treatment planning
study [Chen et al., 2012, Graeff, 2014].
3.4.1 Range Margins and Motion Mitigation
Since conventional geometric margins are not suitable for PT [Park et al., 2012b], margins
based on range changes were used. Another trial comparing photon to proton therapy in NSCLC
patients also used different PTV definitions to incorporate range changes [Roelofs et al., 2012].
As shown in our study, inclusion of range changes leads to increase in PTVPT , up to 4.7 times
compared to PTVSBRT . Furthermore, the difference between PTVs is bigger for smaller tumor
sizes. Patients with bigger tumor volumes (CTV > 2.5 cm3) are therefore better suited for
treatment with PT.
Our results confirm previously published results that interplay can lead to a dose degradation
in treating moving targets with active scanned beam [Bert et al., 2008]. Fig. 3.3 shows the
importance of using 4D dose calculation and motion mitigation techniques in treating moving
targets with particles. Even small motion amplitude can lead to underdosage in CTV without
proper motion mitigation. Considering the average over the 4 simulated motion patterns, 15
patients showed a D99% < 24 Gy under interplay conditions, as opposed to none when using
rescanning (excluding the one patient with reduced target dose). Rescanning proved to be
a strong mitigation technique, with robust results across all targets and different breathing
patterns.
Recent studies suggest that some patients require phase-controlled layer or volumetric rescan-
ning for sufficiently robust target coverage [Mori et al., 2013, Takahashi et al., 2014]. The ad-
vantage of simple slice-by-slice rescanning is that no motion monitoring or assumptions on the
breathing frequency are necessary [Bert and Durante, 2011], but the higher required number
of rescans might increase treatment times due to reduced beam intensities. Another possibil-
ity is to combine rescanning with gating, which was already successfully implemented in clinic
[Rossi, 2016].
3.4.2 RBE and Proton Therapy
Carbon ions exhibit a radiobiological advantage, especially in the Bragg peak region. However,
for high doses as used here the effect of RBE is not well documented and is subject to ongoing
research [Friedrich et al., 2014]. For these high doses RBE for carbon ions should approach a
value between 1 and 2 [Carabe-Fernandez et al., 2007], which is in agreement with values in
our study (around 1.1).
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Coincidently, RBE values in the target at high doses are similar to those used clinically in pro-
ton therapy. Carbon-ions show considerably lower lateral scattering though, which should result
in even better OAR sparing than protons. Our results are in agreement with several in silico stud-
ies comparing SBRT and proton therapy for NSCLC [Roelofs et al., 2012, Kadoya et al., 2010,
Register et al., 2010]. Furthermore, a study made by Kadoya reached the same conclusion as
our study, that patients with larger CTV and/or multiple CTVs would receive less dose from
proton therapy [Kadoya et al., 2010]. A recent phase II trial for patients with multiple sites of
extracranial disease showed good results for photons [Iyengar et al., 2014], however, based on
the findings of Kadoya et al and our study, proton and/or carbon-ion therapy might result in
even better outcome.
3.4.3 Study limitations
The 4D dose calculations were based on a regular breathing pattern, which typically
varies during patient treatment and/or between 4D-CT acquisition and actual treatment
[Verma et al., 2010, Malinowski et al., 2011]. A possible solution was proposed by Boye et
al. to get motion information from 4D magnetic resonance imaging (4DMRI) and use it in
4D dose calculations [Boye et al., 2013].
Furthermore, SBRT treatment plans were done on a static case in contrast to a 4D dose cal-
culation done for PT. This should not influence the results of our study, since motion has a
smaller impact on photon dose distributions [Zou et al., 2014], whereas it is imperative in PT
dose calculations [Bert and Durante, 2011].
There were also differences in treatment planning. PT plans were done by a single person in
a research setting, whereas SBRT plans were made by different people under clinical conditions
with the requirement to finish the plans on time.
Slight changes also existed between the planning CT, used for SBRT treatment plans and
4D-CT used for PT treatment plans, even though 4D-CT was usually acquired right after the
planning CT. The propagation of contours from the planning CT to the 4D-CT and also for the
4D dose calculation rely on deformable image registration (DIR), where even small changes can
effect 4D dose distribution [Kashani et al., 2008]. Results from DIR were thoroughly checked
and results were presented in Chapter 2. However, the transformation of the dose with DIR is
a debated topic and might jeopardize the simulated results, especially with respect to the 4D
target coverage. On the other hand, dose differences in OARs were large and should be robust
against vector field errors in the order a few mm. Nevertheless, further studies are warranted,
possibly using advanced moving phantoms for an experimental validation [Perrin et al., 2014]
and finally also clinical trials. First patients are being treated in thoracic and abdominal regions
with an active beam scanning at the National Institute for Radiological Sciences (NIRS) in Japan
[Mori et al., 2016].
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3.4.4 Application
Scanned carbon ion therapy is available only in a limited number of clinics, mainly due to the
considerably higher cost in comparison to photon linacs. Therefore a careful patient selection
appears sensible. Patients with larger and multiple lesions where SDRT might be limited due to
OAR constraints could be referred to carbon centers. In this study, already lesions larger than
2.5 cm3 were found to benefit significantly stronger from PT.
3.5 Conclusion
SBRT and PT both achieved satisfactory target dose. In most patients PT deposited less dose in
all OARs (including heart, spinal cord, esophagus, trachea and aorta). Patients with multiple
lesions and/or with large target volumes might be preferentially selected for particle therapy.
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4.1 Introduction
Lung cancer is the leading cause of cancer-related death, with approximately 160 000 deaths
in the U.S. in 2014 [Siegel et al., 2014]. More than half of all patients with lung cancer are
diagnosed with stage IV non-small cell lung cancer (NSCLC) [Ramalingam and Belani, 2008,
Iyengar et al., 2014]. The prognosis for stage IV NSCLC is poor, with only 12 months median
survival after first line chemotherapy [Socinski et al., 2013].
A stereotactic body radiation treatment (SBRT) shows good results for treating NSCLC
[Baumann et al., 2009, Fakiris et al., 2009, Grutters et al., 2010, Greco et al., 2011]. Further-
more, several studies have shown that SBRT can be used in the setting of limited metastatic
disease [Rusthoven et al., 2009, Villaruz et al., 2012, Salama et al., 2012, Iyengar et al., 2014].
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Passive scattering particle therapy has also proved as an effective treatment for NSCLC
[Grutters et al., 2010, Tsujii and Kamada, 2012] and it could be considered an alternative to
the standard photon treatment.
It was shown in Chapter 3 that scanned carbon ions (PT) could also be used as a treatment
modality for NSCLC. One of the conclusions of the study shown in Chapter 3 was that patients
with multiple disease sites would especially benefit from PT compared to SBRT. However, limita-
tions of this study were the small number of patients (4) and a single-field uniform optimization
(SFUD) used for treatment planning. Several vital organs, beside the lungs, need to be consid-
ered in the treatment planning for NSCLC patients, such as heart, spinal cord, esophagus and
large vessels. Due to overlapping entry channels SFUD is limited in treating NSCLC, especially
in patients with a tumor in close vicinity to an vital organ. It is not possible to create clinically
acceptable treatment plans with SFUD for such complex geometry.
We hypothesize that intensity modulated particle therapy (IMPT), permits to calculate ade-
quate treatment plans. Furthermore, IMPT should be able to provide a single fraction scheme
in patients, where SBRT is limited by OAR constraints.
The treatment of lung cancer patients with multiple disease sites was investigated using a
state of the art 4D IMPT optimization. Treatment plans were generated with two different
4D optimization techniques and compared with SBRT plans, which were actually used for the
treating patients.
4.2 Materials and Methods
The 4D extension of GSI’s treatment planning system TRiP98 [Krämer and Scholz, 2000,
Richter et al., 2013] was used and modified to create the needed treatment plans. A description
of the modifications and tools used will be given here, alongside with the patient data.
4.2.1 Patient data
In this study, 8 patients with 2 - 5 lung metastases, summing up to 24 metastases in total, were
included. The median lesion size was 4.2 cm3 (25-75% 2.4 - 22.2) and the median peak-to-peak
motion was 5.9 mm (2.7 - 8.1). Further details are given in Table 4.1. The target motion and
PT treatment planning were based on a 4D-CT, consisting of 10 phases (0 - 9), with phase 0
(end-inhale) chosen as a reference phase. A registered positron emission tomography (PET)
scan was used to delineate the clinical target volumes (CTV).
Patients 1 - 3 had no OAR in CTV vicinity (closer than 10 mm), while patients 4 - 8 had at
least one.
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All patients were treated with SBRT at the Chamaplimaud Center for the Unknown, Lisbon
(Portugal), with different fraction schemes. The number of fractions and doses delivered are
given in Table 4.1.
Table 4.1.: Target characteristics, with CTV volumes, peak-to-peak motions, fractionation
schemes and number of fields used for PT treatment planning. Last column shows
which OARs were present in the target vicinity (closer than 10 mm). SA stands for
smaller airways and esoph. for esophagus.
Patient Target Volume (cm3)
Peak-to-peak Fractionation Number OAR in
motion [mm] scheme of fields proximity
1
a 10.2 3.4 1 x 24 Gy 2
b 14.4 2.8 1 x 24 Gy 2
2
a 3.8 5.8 1 x 24 Gy 2
b 4.3 0.8 1 x 24 Gy 2
c 2.7 3.4 1 x 24 Gy 2
d 3.1 2.1 1 x 24 Gy 2
e 0.5 0.5 1 x 24 Gy 2
3
a 139 0.6 1 x 24 Gy 3
b 9.2 2.0 1 x 24 Gy 2
4
a 4 9 3 x 9 Gy 5 SA, esoph., heart
b 0.8 7.8 1 x 24 Gy 2
5
a 3.4 5 1 x 24 Gy 3
b 2.4 4.4 1 x 24 Gy 2
c 2.0 6.3 1 x 24 Gy 2 Heart
d 2.4 6.4 1 x 24 Gy 2 Heart
6
a 20.6 7.4 1 x 24 Gy 4 SA
b 27.1 6.0 1 x 24 Gy 5 SA
7
a 2.3 12 1 x 24 Gy 2
b 0.4 11.8 5 x 7 Gy 5
Heart, esoph.,
stomach
8
a 136 12 3 x 9 Gy 2 Heart
b 12.4 2.5 1 x 20 Gy 2
c 123 14 3 x 9 Gy 2 Heart
d 80.7 17 1 x 22 Gy 3
e 86.7 6.6 1 x 20 Gy 3 SA
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4.2.2 Multiple targets
The TRiP98 optimization works on minimizing the residual of a nonlinear equation system
[Krämer and Scholz, 2000]. The cost function E(N) for the particle number ~N is given by :
E(~N) =
∑
i∈T

Di
plan
− Di
ac t
(~N)

+ θ (Dact − Dmax)wOAR
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j∈OAR

Di
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
(4.1)
For a CT voxel i and j in the target T and the OAR, respectively; Dplan, Dact and Dmax are the
planned, actual and maximum allowed dose, respectively; θ is the Heaviside step function and
wOAR is an OAR specific weight.
The Dact(~N) is calculated as
Dact(~N) =
n∑
k=1
RBE(N)cikN (4.2)
The coefficient cik gives the dose deposition at a voxel i of a pencil beam k, with n being
the number of pencil beams and RBE is the relative biological effectiveness, calculated with the
local effect model or LEM [Elsaesser et al., 2010] .
There is no restriction for the number of targets or fields in the minimizing function, so the
first part of Eq. 4.1 can be expanded to:
E(~N) =
∑
T
∑
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i,T
plan
−
n∑
k=1
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!
(4.3)
However, the setup of raster points in TRiP98 allowed only one target. It was therefore
expanded in a way that a field was designated to a specific target, as displayed in Fig 4.1.
Raster points for each field are created only around the designated target. All fields contribute
dose to all voxels in the optimization. Specifically, k in Eq. 4.3 runs over all pencil beams.
Because the optimization function was not changed, all TRiP98 4D functionalities could be
used, as explained in the next sections.
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All targets were treated with IMPT and 4D optimization. Due to the large optimization
problem for targets 3a - b, 5a - d, 6b, 8a and 8c (targets had a big volume or OARs
were included besides targets in the optimization), a subset of motion states was used
in optimization [Graeff et al., 2012]. To cover most of the different tumor positions, two
extreme motion states (0 and 5) and an intermediate position (7) were chosen.
The same number of fields and the same field angles were used in both techniques.
To reduce the optimization problem, only selected large OARs, such as the heart or the esoph-
agus, were used. Large OARs were manually cropped to the region close to the target. The
dose, however, was calculated on the whole OAR to ensure the validity of results.
For targets with different fractionation scheme (targets 8a-e), TRiP98 was modified to include
an option, allowing specific dose fractions for specific targets.
Figure 4.2.: A schematic presentation of the ITV. (a) The dark gray ellipses show the margins
needed for specific fields to account for range changes in different motion states.
When a common target volume for two perpendicular fields is generated (v black
contour) it creates unnecessary lateral extension of both fields, as shown by the
dark gray entry channels. A solution is shown in (b). Rather than using standard,
geometric margins, both fields use the same geometry, however the conversion of
geometry to WEPL is altered for each field. The plot in (b) shows the standard (solid
line) and an altered conversion (dashed-doted line) for a beam passing a homoge-
neous CTV. The altered conversion increases the WEPL extent and thus implicitly
increasing margins for a single field only. Figure taken from [Graeff et al., 2012]
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4.2.4 Treatment planning
An isotropic margin of 3 mm was added to each CTV to account for uncertainties in treatment
delivery. A WEPL-ITV was constructed on the CTV with margins for each individual field, which
was than used either in the optimization (ITV) or for the raster setup (4Dopt). Due to large
memory demands, the targets in each lung were optimized separately.
The planning objective was 99% of each target volume should receive at least 100% of the
planned dose (D99% ≥ 100%). Two dose limitation were used for OARs, as defined in the AAPM
task group [Benedict et al., 2010]. The first limitation was the maximum dose to a single voxel
DMax and the second the maximum dose deposited to a specific OAR volume DThreshold . All
limits are summarized in Table B.1.
After the optimization the 4D-dose was calculated for two motion periods (3.6 sec and 5.0
sec) and two starting phases (0◦ and 90◦) as explained in Section 3.2.4. The relative biological
effectiveness (RBE) was calculated with LEM IV [Elsaesser et al., 2010]. Alpha beta ratio of 6
and 2 was used for the target and normal tissue, respectively.
The motion was mitigated by applying slice-by-slice rescanning to each plan. The number
of rescans was limited by the number of particles in a single raster point, which should not be
lower than 8000 due to the monitoring precision. The maximum number of rescans was limited
to 20.
A detailed explanation of the SBRT treatment planning is given in Section 3.2.3.
For patients 4 - 7 OAR doses could not be sufficiently reduced in optimization. It was necessary
to add margins to the OAR and then subtract the OAR plus margins from the target. For SBRT
the OAR plus margins was subtracted from PTV, which included 3 mm isotropic margins on a
geometrical ITV. In PT geometrical ITV was not used, so in each of the 10 motion states, OAR
plus margins was subtracted from CTV plus 3 mm.
In the first try the OAR was included in the optimization with different weights (wOAR in
Eq 4.1) and without any subtraction from the target. For any 3D treatment plan with an ac-
ceptable dose distribution after the optimization, a 4D dose was calculated and OAR and target
dose were inspected. If the plan was rejected, the optimization was repeated, adding the OAR
subtraction from the target volume.
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4.2.5 Dose escalation
A single fraction of 24 Gy could not be used in SBRT treatment for targets 4a, 7b and 8a-e due
to OAR dose constraints. For these targets additional PT plans were generated with 1 x 24 Gy
fractionation scheme, in order to estimate if PT could respect OAR constraints for these targets,
while delivering 1 x 24 Gy.
4.2.6 Data evaluation
For a comparison of the target coverage, the minimum dose in 99% of the target volume (D99%)
was evaluated. DMax and DThreshold were used in the OAR dose comparison. DMax and DThreshold
were normalized to the respective limits in the fractionation scheme used, see Table B.1. Addi-
tionally, the volume receiving 20% of the planned dose (V20%) was used to assess the ipsilateral
lung dose.
Paired t-tests were performed to compare the dose metrics mentioned between SBRT, ITV and
4Dopt. A p-value < 0.05 was considered as significant.
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4.3 Results
An example of different treatment plans for three patients are shown in Fig. 4.3.
4.3.1 Target Coverage
The results for CTV D99% for all patients are shown in Table 4.2. All SBRT plans were approved
by a physician, even though the prescribed dose for patients 4 - 6 was not met due to an OAR
proximity. Target 7b D99% for PT was below prescription and SBRT delievered full dose. Average
CTV D99% was 97, 95 and 98% for ITV, 4Dopt and SBRT, respectivelly, There was a significant
difference between ITV and 4Dopt and SBRT and 4Dopt.
Table 4.2.: CTV D99% for tITV, 4Dopt and SBRT for 8 patients. The results for ITV and 4Dopt are
shown as median (range) across the different motion types.
Patient Target
CTV D99% (%)
ITV 4Dopt SBRT
1
a 101.0(101.0 - 101.0) 101.0(101.0 - 101.0) 100.0
b 101.0(101.0 - 102.1) 101.0(101.0 - 101.0) 100.0
2
a 101.0(101.0 - 102.1) 100.0(99.0 - 102.1) 106.3
b 102.1(102.1 - 102.1) 102.1(102.1 - 102.1) 103.1
c 101.0(100.0 - 101.0) 101.6(101.0 - 102.1) 104.2
d 102.1(101.0 - 102.1) 102.1(102.1 - 102.1) 107.3
e 101.0(101.0 - 101.0) 101.0(101.0 - 102.1) 108.3
3
a 101.0(101.0 - 101.0) 101.0(101.0 - 101.0) 101.0
b 98.4(97.9 - 99.0) 97.9(97.9 - 97.9) 102.1
4
a 65.3(63.9 - 69.4) 70.4(68.5 - 72.2) 66.7
b 101.0(100.0 - 102.1) 100.5(100.0 - 102.1) 103.1
5
a 100.0(99.0 - 101.0) 100.0(100.0 - 100.0) 101.0
b 101.6(100.0 - 102.1) 97.9(96.9 - 99.0) 101.0
c 95.3(94.8 - 96.9) 94.3(92.7 - 94.8) 99.0
d 99.0(97.9 - 99.0) 99.5(99.0 - 100.0) 94.8
6
a 89.1(88.5 - 90.6) 85.4(85.4 - 87.5) 69.8
b 78.6(77.1 - 79.2) 72.4(71.9 - 72.9) 69.8
7
a 102.1(102.1 - 102.1) 99.0(99.0 - 99.0) 101.0
b 83.9(82.1 - 85.7) 75.0(75.0 - 75.0) 100.0
8
a 100.0(100.0 - 100.9) 99.5(99.1 - 100.9) 105.6
b 101.3(100.0 - 102.5) 100.0(100.0 - 101.3) 105.0
c 100.0(99.1 - 100.0) 99.5(97.2 - 100.0) 106.5
d 102.3(102.3 - 102.3) 89.8(89.8 - 90.9) 102.3
e 102.5(102.5 - 102.5) 91.9(91.3 - 92.5) 101.3
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4.3.2 Dose in OARs
DMax and DThreshold for 8 OARs are shown in Table 4.3. Dose volume histograms (DVH) for
patients 4, 6 and 7 are shown in Fig. 4.4. There was a significant difference between PT and
SBRT in DMax and DThreshold for heart, spinal cord, esophagus and aorta. No significant differ-
ence was observed for DMax and DThreshold in the smaller airways. No significant difference was
observed in the dose to any OAR between the different motion types or between ITV and 4Dopt.
The overall OAR difference for patients between SBRT and ITV was significant, 17 (4 - 52)%
and 27 (8 - 55)% of OAR limits for DMax DThreshold , respectivelly. The ipsilateral lung V20% was
14.5(0.0 - 48.7), 14.4(0.0 - 43.7) and 29.8 (5.8 - 89.2)% for ITV, 4Dopt and SBRT, respectively.
Both, ITV and 4DITV ipsilateral lung V20% was significantely different from SBRT.
The margins used for the OAR subtraction for PT and SBRT can be found in Table C.11.
All treatment plans exceeded the DMax limit for the smaller airways in patients 4, 6 and 8
and for the heart in patient 6. Additionally, the SBRT esophagus and heart DMax limits were
exceeded in patients 4 and 8, respectively.
Table 4.3.: OAR DMax , DThreshold and ipsilateral lung V20% of all patients for ITV, 4Dopt and SBRT.
There was a significant difference between PT and SBRT for all OARs, except smaller
airways’ DMax . DMax and DThreshold doses are normalized to the corresponding OAR
limits in the fractionation scheme used (see [Benedict et al., 2010]). The data is dis-
played as median (range).
OAR
ITV 4Dopt SBRT
DMax (%)
heart 62.0(0.0 - 100.0) 59.5(0.0 - 97.0) 82.5(20.0 - 103.0)
spinalcord 13.0(0.0 - 48.0) 12.0(0.0 - 55.0) 60.0(21.0 - 79.0)
smaller airways 72.5(0.0 - 130.0) 71.0(0.0 - 117.0) 72.5(0.0 - 171.0)
esophagus 9.0(0.0 - 79.0) 8.0(0.0 - 99.0) 70.5(20.0 - 101.0)
aorta 17.5(8.0 - 61.0) 15.0(7.0 - 61.0) 45.0(15.0 - 74.0)
DThreshold (%)
heart 15.5(0.0 - 59.0) 16.0(0.0 - 53.0) 62.5(19.0 - 98.0)
spinalcord 11.0(0.0 - 45.0) 10.0(0.0 - 53.0) 66.5(28.0 - 95.0)
smaller airways 28.0(0.0 - 97.0) 26.5(0.0 - 89.0) 68.5(0.0 - 99.0)
esophagus 1.0(0.0 - 17.0) 1.0(0.0 - 20.0) 49.0(17.0 - 99.0)
aorta 5.5(0.0 - 30.0) 5.5(0.0 - 28.0) 34.5(12.0 - 59.0)
V20% (%)
ipsilateral lung 14.5(0.0 - 48.7) 14.4(0.0 - 43.7) 29.8(5.3 - 89.2)
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4.3.3 Dose escalation
With in PT the 1 x 24 Gy fractionation scheme could be used for targets 8a-e, violating only
DMax for the smaller airways (180%) and the heart (110%), to a similar extent as was found
acceptable in SBRT. The SBRT for patient 8 was limited by the heart DMax and DThreshold which
were 102% and 93%, respectively. SBRT delivered a mean heart dose of 3 Gy in a single fraction
(out of three), whereas PT’s mean heart dose was 0.8 Gy. The difference in the heart dose can
be seen in Fig 4.5.
For targets 4a and 7b the 1 x 24 Gy fractionation scheme could not be generated with PT.
Either the target coverage was low (CTV D99% < 50%) or the esophagus DMax and additionally
the stomach DMax for target 7b were exceeded.
Figure 4.5.: Dose volume histogram for the heart dose of the Patient 8. SBRT (red) plan was
delievered in a 3 x 9 Gy fractionation scheme. The ITV PT plans were generated for
the same fractionation scheme (green) and with a dose escalation 1 x 24 scheme
(blue). The dose was normalized to DMax heart limit in respective fractionation
scheme - 30 Gy in 3 x 9 Gy and 22 Gy in 1 x 24 Gy.
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4.4 Summary and Discussion
Clinically valid SBRT plans have been compared to PT treatment plans for NSCLC patients with
multiple metastases. To the best of our knowledge, this is the first study treating multiple NSCLC
metastases with IMPT. A novel approach was used to handle multiple targets, combined with
state of the art 4D IMPT treatment planning. Furthermore, 4D PT doses were calculated for
different motion types.
PT on average delivered less dose to OARs, while still having comparable target coverage
to SBRT. The most important difference was found in the heart dose, with DThreshold being
on average 6 times lower in PT compared to SBRT. A recent trial, RTOG 0617, has shown,
that a higher mortality rates could be attributed to higher heart dose for NSCLC patients
[Bradley et al., 2015]. Furthermore, as seen in Table 4.3, the median DThreshold for all OARs
is below 30% and DThreshold exceeds 90% in only one OAR in one patient. For SBRT DThreshold
comes close to the limit in all OARs, except the aorta. There was no need to include DThreshold
in treatment planning, whereas it is imperative in SBRT.
For patients with a complex geometry (4 - 8) PT maintained or even improved target coverage
in most cases, while reducing doses to OARs. The exception was target 7b, where CTV D99%
was low (84% and 75% for ITV and 4Dopt, respectively), due to the DMax constraints of the
esophagus and the stomach. The large motion of target 7b (11.8 mm) and the small target
volume (0.4 cm3) contributed to a poor PT plan, whereas SBRT was able to deliver the full
dose to the target and adhering to OAR constraints. This supports our claim in Chapter 3 that
targets with larger volume would benefit most from PT. Furthermore, for small targets with
large motion in OAR vicinity, PT generates worse plans than SBRT. It should be noted, however,
that integral doses for all OARs are still lower for PT as seen in Fig 4.4. The only limitation for
PT is usually the OAR’s DMax .
The biggest advantage of PT could be seen in Patient 8, where the fractionation scheme could
be changed to 1 x 24 Gy. The large total target volume of Patient 8 could be irradiated with less
overall dose and hence significantly reduced the dose to all OARs. Most notably, the heart dose,
which was the limitation factor for SBRT. The difference of 2 Gy mean heart dose in a single
fraction is tremendous and could influence the potential outcome for the specific patient. Again,
this confirms our claim of PT benefit for large targets. Due to the OAR constraints of targets
4a and 7b, located adjacent to important serial organs, no fractionation escalation was possible
with PT.
There was a small difference in the average target coverage between ITV and 4Dopt. The most
notable difference was in targets 8d and 8e, where CTV D99% was 10% lower for 4Dopt. For this
patient 4Dopt was performed on a subset of the 4D-CT states, which may be inadequate due to
the large motion of target 8e (17 mm). In a future study, the number of voxels included in op-
timization should be reduced, without reducing the target coverage. A possible solution would
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be an adaptive dose grid [Prall et al., 2016b]. There was no significant difference between ITV
and 4Dopt in the doses to OARs.
Even though PT deposits less dose to OARs with the same or even better target coverage, there
is still room for improvement in PT 4D treatment planning. An implementation of multi-criteria
objective planning should bring even better dose distribution and bring possibility to choose
between trade-offs [Breedveld et al., 2007, Chen et al., 2010]. Additionally, the multiple target
optimization in PT would benefit from a shell around PT where the dose would be minimized.
Therefore the excessive dose in healthy tissue would be further reduced. An introduction of
a shell, however, would further enlarge the optimization problem, which is big already for
complex geometries (patient 4 - 8). An adaptive optimization grid could be a possible solution
here as well [Prall et al., 2016b].
In Chapter 3 additional range margins to account for range uncertainties could be used in
the treatment planning, due to SFUD. Because we did not use field specific PTVs, it was not
possible to include range uncertainties in this study. Instead of creating field specific PTVs to
include range uncertainties, a solution was proposed to include uncertainties in the optimiza-
tion process itself [Pflugfelder et al., 2008, Unkelbach et al., 2009, Fredriksson et al., 2011,
Chen et al., 2012]. Chen et al. have implemented a robust optimization in a multi-criteria
optimization as well [Chen et al., 2012]. Furthermore, in a recent treatment planning study
by Liu et al. [Liu et al., 2016b] a 4D robust optimization was demonstrated, with better results
over 3D robust optimization for NSCLC patients. However, only the breathing starting phase was
used as an uncertainty, whereas different motion types should be considered. The disadvantage
of 3D and 4D robust optimization is the enlargement of the optimization problem.
Patient 4 DMax esophagus dose ranged over 1.3 Gy across different motion types in 4Dopt,
showing the necessity of making treatment plans robust against motion uncertainties, especially
in the hypo-fractionated regiment. Furthermore, OAR doses that are under the limits after opti-
mization, may exceed them after calculating the 4D dose. The ITV and 4Dopt approaches take
into account range changes in different motion states, however they do not address interplay.
This could be solved with a complete 4D optimization [Graeff et al., 2013], where a 4D raster
treatment plan is generated and each motion state has a designated treatment plan.
Apart from 4D robust optimization, the effect of the motion could be minimized by us-
ing other motion mitigation techniques, such as gating. Furthermore, gating could im-
prove the target coverage, where the planned dose was not met. Gating, together with
rescanning, has already been successfully implemented clinically for active beam scanning
[Rossi, 2016, Mori et al., 2016] and it might be essential to use it in hypo-fractionated treat-
ment of moving tumors [Richter et al., 2014].
A recent review showed good local control rates between 66 - 92% for patients treated with
SBRT for in-field recurrent tumors [Amini et al., 2014]. However, there were grade 4 and 5
complications present. A study by Trovo et al.showed grade 5 pneumonia in 6% of patients
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treated [Trovo et al., 2014]. As shown in our study, PT delivers less dose to the OARs, ipsilateral
lung in particular, and could hence reduce the number of treatment-related complications.
4.5 Conclusion
PT delivers less dose to OARs compared to SBRT in NSCLC patients with multiple disease sites,
while maintaining target coverage. One patient with a large total target volume could be irradi-
ated with 1 x 24 Gy, whereas it could not with SBRT. There was a small difference between the
two 4D treatment planning techniques.
Patients with multiple NSCLC disease site have a poor prognosis, with a median survival
shorter than a year. A treatment with SBRT can prolong the patient’s life, however there is a
10% chance of death due to the severity of the treatment. PT could maintain the SBRT survival
rate, while tremendously reducing treatment related side effects.
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5 Discussion
This is the first in silico study directly comparing clinical stereotactic body radiation therapy
(SBRT) with scanned carbon-ions (PT) for non-small cell lung cancer (NSCLC). Our results show
that PT could be considered an alternative to SBRT, with the same tumor coverage and less dose
to OARs. Furthermore, the study was expanded to patients with multiple NSCLC disease sites.
With a state of the art 4D optimization, intensity modulated particle therapy (IMPT) was able
to generate treatment plans with less OAR doses and comparable target coverage to SBRT. It
was possible to plan for a a single fraction ablative dose with IMPT for a specific patient with
5 lesions, where SBRT was limited due to excessive heart dose. The mean heart dose could be
reduced by an order of magnitude.
The treatment of NSCLC with PT is influenced by interplay effects between the tumor motion
and the beam scanning. It was shown that rescanning offers adequate motion mitigation.
PT offers precise dose shaping but it can thus also be more prone to uncertainties. Calcu-
lation of time-resolved (4D) doses can be significantly affected by errors in deformable image
registration (DIR) [Heath and Seuntjens, 2006]. Special tools were developed in the scope of
this thesis to ensure DIR quality assurance (DIRQA). All tools were tested on a large dataset to
ensure their validity.
5.1 Deformable image registration and validation
A single DIR algorithm was used in this study, B-Spline. In contrast to Demons algo-
rithm, B-Spline should handle large deformations well as present in lung and cardiac 4D-CT
[Tang et al., 2013]. The DIR for lung 4D-CT had only small inconsistencies and here B-Spline
can be considered sufficient. On the other hand, the results suggest that B-Spline is inadequate
for DIR of a pig cardiac 4D-CT. The parameters used in B-Spline DIR were similar in both cases
of DIR. This could be improved by systematically investigating the effect of parameters on DIR
quality.
The advantage of using open-source software for DIR, as explained in Section 2.2.2 is that
different DIR algorithms, optimization metrics and image types can be used. They can be ac-
cessed either using existing libraries, such as ITK [Yoo et al., 2002], or by writing designated
software [Fedorov et al., 2015]. In the future, different DIR algorithms have to be implemented
and tested for various anatomical sites.
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In this study, DIR was used for contour propagation and 4D dose calculations. The 4D dose
calculation requires accurate DIR in each voxel, since the dose is propagated with the resulting
vector field. This was ensured by calculating the vector field Jacobian and ICE voxel-wise.
Tests in the DIRQA module were divided into two groups - qualitative and quantitative. Qual-
itative tests are false color and checkerboard; they provide an overview of the DIR result. How-
ever they do not give any information of the vector field quality and it is impossible to review
the sheer amount of data. An example of the disadvantage of the qualitative test could be seen
in the pig cardiac 4D-CTs, where qualitative test did not show any errors in DIR, but errors were
observed in the vector fields.
The quantitative tests used in the DIRQA module are landmark distance, absolute difference,
Jacobian and ICE. Absolute difference, Jacobian and ICE have undergone an extensive test-
ing. The results suggest that absolute difference gives us the least information about DIRQA,
apart that it has to be lower after the DIR. We have shown that bigger deformations yield
more deviations in Jacobian and ICE, which was also previously reported [Stanley et al., 2013].
Furthermore, we have confirmed that Jacobian should always be positive for a successful DIR
[Rey et al., 2002]. Additionally, our results show that ICE should be smaller than the maxi-
mum vector field magnitudes. Any deviations from the mentioned trends should be thoroughly
examined.
There are additional vector field validation methods beside Jacobian and ICE, such as vec-
tor field curl [Schreibmann et al., 2012], unbalanced energy [Zhong et al., 2007], permutation,
and analysis of the variance (ANOVA) tests [Klein et al., 2009]. It was demonstrated in a study
by Salguero et al. [Salguero et al., 2011] that DIR errors greater than 1 mm can lead to large
dose errors in high-dose gradient regions. Therefore the DIR accuracy has to be quantified at
each image voxel in the high-dose gradient regions. In our study, a focus was given on a com-
plete registration to find potential errors. However, in future studies the regions of interest
used should be around the target, where high-dose gradients can occur. Furthermore, the effect
of the image and vector field downsampling on DIRQA and on 4D dose calculation should be
assessed.
Due to the lack of landmarks in all 4D-CTs, landmark distance was not included in the veri-
fication. Two contour based validations, dice similarity coefficient [Varadhan et al., 2013] and
Hausdorff distance [Huttenlocher et al., 1993] are planned to be implemented in the DIRQA
module. In the literature many approaches have been reported to assess DIRQA with land-
marks or contours. A study by Hardcastle et al. [Hardcastle et al., 2012] compared demons
and Salient-Feature-Based registration with dice coefficients between propagated and physician
drawn contours. A multi-institutional study by Brock et al. [Brock, 2010] compared differences
in propagated and oncologist drawn landmarks. A method has been developed by Castillo et al.
[Castillo et al., 2009] to automatically identify landmark points in lung patients images. How-
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ever, visual based evaluations are of limited use in regions of uniform image intensity and by
the number of the objects being tracked [Kashani et al., 2008, Liu et al., 2012].
5.2 Treating non-small cell lung cancer with particle therapy
The results in this thesis suggest that PT could be used as a treatment modality for NSCLC.
It delivers a comparable target dose to SBRT, while significantly reducing the dose to OARs.
The lower mean heart could be crucial in improving patient survival based on a recent trial
from RTOG 0617 [Bradley et al., 2015]. The mean dose to the heart would be on average 1 Gy
smaller with PT than with SBRT. For patients with multiple disease sites, it would be on average
4 Gy smaller, reaching up to 9 Gy. Similar results were observed when comparing protons to
SBRT [Georg et al., 2008].
The advantageous dose profile of PT permits to use few, selected fields with narrow entry
channels, avoiding the dose bath needed in SBRT to achieve high dose gradients in the target.
Hence the benefit of PT is most profound for patients with large total target volume, whether a
large single target or multiple targets. Studies suggest, that SBRT is limited for large tumors
(radius > 5 cm) and multiple primary tumors [Timmerman et al., 2006, Georg et al., 2008,
Westover et al., 2012], making PT a promising alternative.
Besides large tumors and multiple primary tumors, SBRT is also limited in treating centrally lo-
cated tumors and tumors close to the chest wall. In a study done at Francis H. Burr Proton Ther-
apy Center patients who could not be treated with SBRT, due to the scenarios mentioned, were
treated with passive proton beam in 3 - 5 fractions, delivering 42 - 50 Gy [Westover et al., 2012].
They observed similar tumor local control rates as in SBRT (100% in a two year follow-up) with
limited toxicities. It should be stressed that these patients were rejected from SBRT treatment
due to the complexity and regardless proton therapy achieved similar results to SBRT.
In addition to a narrow entry channel, PT has sharper dose gradients and can conform the
dose better to the target. Fig 3.3 shows that 80% of the targets have D99% between 100 - 107%
and 100 and 102% for SBRT and PT, respectively. Sharper dose gradients also enable less dose
to the surrounding tissue. Nevertheless, a fraction escalation was possible only in one patient
out of three. The limitation in the two patients with unsuccessful fraction escalation was the
esophagus maximum single point dose DMax , which is 15 Gy in 1 x 24 Gy scheme. In both
patients the esophagus was closer than 2 mm to the target, making the limitation impossible to
respect without sacrificing target dose. Furthermore, for one of these two patients, PT could not
deliver planned target dose, whereas SBRT could. Beside complex geometry, the tumor had a
small volume and large motion. This patient exhibits the advantage of SBRT over PT.
PT has to take into account particle range uncertainty, which can come from the conver-
sion of HU to stopping power [Schneider et al., 1996] or from anatomical changes in the pa-
tient [Unkelbach et al., 2009]. We included range uncertainties with expansion of the target in
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beam’s eye view, which resulted on average in 1.5 times bigger target volume for PT compared
to SBRT. Another way to include range and other uncertainties is robust optimization, resulting
in IMPT plans more resilient to uncertainties [Unkelbach et al., 2009, Chen et al., 2012]. We
are planning to include robust optimization in a future study, where SFUD, IMPT and robust
IMPT plans will be compared for NSCLC patients.
While tumor motion influences photon treatment, it can be mitigated with proper margins
[Zou et al., 2014]. On the other hand, effects can be substantial when treating moving targets
with scanned particle therapy [Bert et al., 2008]. It was shown in this thesis that rescanning
is an adequate motion mitigation technique. However, rescanning has a degree of uncertainty,
especially regarding OAR DMax . In a hypofractionated treatment these limits are strict and the
exact dose to the OAR must be known. A possible solution would be to simulate rescanning and
4D delivery in the optimization process itself. Such a solution is not yet feasible due to the com-
plexity of the problem. Another solution could also be phase-controlled rescanning with greatly
reduced uncertainty in the mitigation outcome [Mori et al., 2013, Takahashi et al., 2014]. How-
ever, it requires motion monitoring and complicates the treatment delivery.
Gating is a commonly used motion mitigation technique in both photon and particle treat-
ment. While it provides less motion-induced dose errors, it prolongs the treatment time. A
recent study by Zhang et al. [Zhang et al., 2015] included different breathing patterns, ob-
tained from MRI, on a 4D-CT and calculated 4D doses for liver cancer patients treated with
proton therapy. They have shown that a gating window of 3 mm can result in a 10% efficiency
of a duty-cycle, substantially prolonging the treatment. Additionally, they have shown that nei-
ther volumetric or slice-by-slice rescanning could achieve good target coverage. However, this
was obtained with a combination of gating and rescanning. Their results suggest that a combi-
nation of gating and rescanning would currently be the best solution for treating NSCLC patients
with PT.
Between rescanning, gating and beam tracking is the most precise technique, since it re-
quires no internal target margins [Bert and Durante, 2011]. Current clinical implementations
of tracking in photon radiotherapy [Kilby et al., 2010, Keall et al., 2014] can not be directly
used in particle therapy, since they only provide the position of single internal points. Fassi et
al. [Fassi et al., 2015] were able to account for inter- and intra-fractional variability of patient’s
anatomical configuration with a designated modeling technique [Fassi et al., 2014]. The mea-
sured median of water-equivalent path length in target was within 2 mm of a simulated one.
For an actual clinical implementation it will be necessary to test the model on a large patient
dataset.
All three techniques, rescanning, gating and beam tracking, essentially adapt 3D treatment
plans to a 4D situation and thus have limitations. Full 4D-optimization, on the other hand,
creates a 4D treatment plan, with each motion state in the 4D-CT having a designated treatment
102
plan. A full 4D-optimization has been successfully implemented and verified experimentally at
GSI [Graeff et al., 2013].
Recent advances in photon radiotherapy allow the use of non-coplanar beams, a so-called 4pi
optimization [Dong et al., 2013b]. A study by Dong et al. [Dong et al., 2013a] showed that
4pi yielded better target coverage and OAR sparing than SBRT for NSCLC patients. They have
reported a reduction of DMax in the heart, the esophagus and the spinal cord by 32%, 72% and
53%, respectively, showing the potential of a 4pi optimization. According to this thesis, PT is
able to reduce the DMax even further, with a reduction of 57%, 87% and 83% for the heart,
the esophagus and the spinal cord, respectively. The numbers, however, should be compared
with caution, since they were obtained from a different set of patients. A future study, directly
comparing SBRT, 4pi and PT for NSCLC is thus warranted.
In a recent phase II study by Iyengar et al. [Iyengar et al., 2014] patients with stage IV NSCLC
were treated with SBRT and chemotherapy. They have irradiated 52 targets in 24 patients, 16
of them had more than one target. The results were promising, with 20 months median overall
survival, compared to 9 months when treating with chemotherapy only [Tsao, 2016]. Results
in this thesis show that patients with multiple disease sites would especially benefit from PT.
Based on the poor prognosis of stage IV NSCLC patients and on the results published by Iyengar
et al., stage IV NSCLC patients could be eligible candidates for PT treatment. Additionally,
such patients usually exhibit chronic obstructive pulmonary disease and less dose to the lung
is warranted [Westover et al., 2012]. This further supports our claim, since our study showed
substantial differences in the doses to the ipsilateral lung (V20% was on average 15% smaller in
PT for patients with multiple disease sites) and contralateral lung as well - 70% of patients did
not receive any dose to the contralateral lung, whereas SBRT deposited dose in contralateral
lung in all patients.
The results of a multi-institutional randomized trial, RTOG1308 [RTOG, 2014], comparing
photons and particle therapy in treating NSCLC, will have an important impact on treating
NSCLC. The trial started in 2014.
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6 Conclusion and Outlook
To ensure the tumor will receive the planned dose and the dose to the normal tissue will not
exceed the prescribed limits, it is imperative to include a time-resolved (4D) dose calculation in a
scanned carbon-ions (PT) treatment planning. A 4D dose calculation is based on the deformable
image registration (DIR). DIR is a complex problem and hence prone to errors. Since any
errors in DIR may significantly affect the 4D dose calculation, a DIR quality assurance must be
conducted before using DIR in the PT treatment planning for lung cancer.
To make PT treatment plans more robust against the uncertainties, there is an emerging trend
of including uncertainties in the optimization process itself, the so-called robust optimization.
A standard geometrical margin definition inherited from the photon radiotherapy may be inad-
equate in PT. The robust optimization, however, can substantially improve the treatment plans
[Chen et al., 2012]. Furthermore, the robustness optimization is now computationally possible
even for a 4D optimization [Liu et al., 2016b], bringing treatment of lung cancer patients with
PT closer to reality. Future studies on treating lung cancer with PT should definitely include a
robust 4D dose optimization.
The uncertainties in the radiation treatment could drastically be reduced by employing
real-time imaging at the moment of irradiation. This was achieved by merging MRI and
photon Linac, a promising new technology in the field of radio therapy. The application
is being realized in a few clinics worldwide and first patients will be treated in the near
future [Lagendijk et al., 2016]. Although the challenge of combining PT with MRI may be
greater for particles than for photons, studies have shown the feasibility of a such combina-
tion [Hartman et al., 2015]. In addition, it was shown that particles could be used for imaging
purposes as well, opening a wide field of new possibilities for PT [Prall et al., 2016a].
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Based on the results of this study, PT should be considered as a treatment modality for the
non-small cell lung cancer. PT not only delivers the same dose to the tumors as the tumors as
the state of the art photon therapy (SBRT), but also tremendously reduces the normal tissue
irradiation.
PT would be especially beneficial for patients with large tumors or with multiple disease sites,
because the dose bath is much smaller than with SBRT. This could play a crucial role in some
patients in which PT could deliver the full ablative dose in a single fraction, whereas SBRT is
limited due to over irradiating normal tissue.
Patients with an advanced stage of lung cancer have an extremely poor prognosis, with a
median survival rate of only nine months. Currently the best treatment, a combination of
chemotherapy and SBRT, is able to extend the patient survival rate to 20 months. However,
every tenth patient will die due to treatment-related effects. We have shown that PT has the
potential to significantly reduce the radiation-related side effects and hence tremendously im-
prove the survival rate. PT should therefore definitely be further investigated as a lung cancer
treatment modality, especially for an advanced stage disease.
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A.1 Patient hierarchy
Patient hierarchy follows a subject hierarchy principle in Slicer. It was designed for a clear
overview of the registration process, DIRQA and all resulting files. Another reason is to track
DIR and DIRQA in case if they are interrupted by Slicer crash. DIR and DIRQA files can be
quite large and can cause Slicer to run out of memory. With patient hierarchy Slicer is able to
continue work from where it was interrupted rather than starting anew.
There are several levels in patient hierarchy. Each level also has different attributes, where
details regarding each level can be written.
• Level 1: Patient name - separates different patients.
• Level 2: Registration node - separates between different registrations, e.g. between dif-
ferent imaging modalities or between 4D-CT phases.
Attributes:
- The file directory of images, vector fields and registration quality files.
- Number of phases to be registered.
- Reference phase
• Level 3: Registration set - specific registration phase. Registration is done between all
phases and the reference one. There have to be at least two phases
• Level 4: Node - can be either an image, a vector field, an inverse vector field or any of
DIRQA nodes (see Section 2.2.3).
Attributes:
- Exact file paths for specific node.
- Statistical analysis if node is absolute difference, Jacobian or inverse consistency (see
Section 2.2.3).
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The patient hierarchy can be constructed in two ways. The first option is to manually create
the whole patient hierarchy, from top to bottom level, with necessary attributes. Second option
is to use an automatic script to look for files on hard drive and create corresponding levels. The
second option is possible only by using proper naming conventions for file names and locations.
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B Appendix of Chapter 3
B.1 Organs at risk dose limits
OAR dose limits used in SBRT and PT treatment planning for different fractionation schemes are
shown in Table B.1. Two limits were used. The first limitation was a maximum dose to single
voxel DMax and the second a maximum dose deposited to a specific OAR volume DThreshold .
Table B.1.: Dose constraints for various OARs for 1, 2 and 3 fractions, denoted as respective
numbers. Limits were used in SBRT and PT treatment planning. Data taken from
[Benedict et al., 2010]
Critical Threshold dose (Gy) Maximum point dose(Gy)
Organ volume (cc) 1 2 3 1 2 3
heart 15 16 22 24 30 32 38
spinal cord 0.35 10 14 18 21.9 23 30
smaller airways 0.5 12.4 13.3 18.9 23.1 21 33
esophagus 5 11.9 15.4 17.7 25.2 19.5 35
trachea 4 10.5 20.2 15 30 16.5 40
aorta 10 31 37 39 45 47 53
stomach 10 11.2 12.4 16.5 22.2 18 32
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B.2 Target coverage
Target coverage for SBRT and PT. For PT target coverage was calculated in 3D case on state 0
and 5 (3D-Dose0% 3D-Dose50%;) 4D doses were calculated for two different breathing periods
(3.6 s and 5s) and for two starting phases (0◦ and 90◦). 4D doses were calculated without
motion compensation (4D-Doseinterpla y) and with rescanning as a motion mitigation technique
(4D-Doserescanning).
Table B.2.: Target coverage for PT and SBRT as CTV D99%. PT was calculated two static cases (3D,
state 0 and 5) and 8 4D cases - two breathing periods: 3.6 and 5 s (Per 3s and Per 5s),
two starting phases: 0◦ and 90◦ (Ph0 and Ph90) and without rescanning (interplay)
and with rescanning. All values are displayed as percentage of the planned dose.
Tar- 3D 4D interplay 4D rescan
SBRTget State State Period 3.6s Period 5s Period 3.6 s Period 5s
0 5 Ph0 Ph90 Ph0 Ph90 Ph0 Ph90 Ph0 Ph90
1 101.04 101.04 98.96 98.96 98.96 100.0 101.04 101.04 101.04 101.04 103.13
2 102.08 102.08 101.04 98.96 100.0 97.92 101.04 102.08 102.08 101.04 101.04
3 104.17 105.21 101.04 97.92 95.83 97.92 104.17 106.25 103.13 107.29 101.04
4 100.0 100.0 92.86 100.0 92.86 92.86 96.43 103.57 100.0 103.57 100.0
5 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04
6 102.08 103.13 100.0 100.0 98.96 100.0 100.0 100.0 101.04 102.08 101.04
7 102.08 102.08 97.92 95.83 92.71 94.79 101.04 100.0 101.04 102.08 100.0
8 102.08 102.08 100.0 100.0 98.96 97.92 102.08 101.04 102.08 102.08 101.04
9 101.04 102.08 98.96 98.96 96.88 97.92 101.04 100.0 101.04 101.04 101.04
10 100.0 100.0 98.96 100.0 98.96 100.0 101.04 100.0 101.04 100.0 102.08
11 102.08 102.08 98.96 98.96 98.96 97.92 101.04 101.04 101.04 101.04 100.0
12 102.08 102.08 98.96 100.0 98.96 97.92 101.04 102.08 101.04 101.04 100.0
13 102.08 102.08 97.92 97.92 96.88 96.88 102.08 100.0 101.04 101.04 106.25
14 101.04 101.04 100.0 100.0 98.96 98.96 101.04 101.04 101.04 101.04 103.13
15 101.04 102.08 100.0 97.92 98.96 95.83 101.04 100.0 101.04 101.04 104.17
16 101.04 100.0 95.83 96.88 97.92 96.88 100.0 98.96 101.04 100.0 107.29
17 102.08 102.08 100.0 100.0 98.96 96.88 101.04 102.08 102.08 101.04 108.33
18 101.04 101.04 95.83 100.0 96.88 94.79 101.04 101.04 101.04 101.04 101.04
19 101.04 98.96 98.96 96.88 97.92 97.92 98.96 98.96 100.0 98.96 104.17
20 82.29 81.25 85.42 85.42 83.33 87.5 85.42 86.46 86.46 85.42 70.83
21 101.04 101.04 97.92 96.88 94.79 96.88 98.96 102.08 100.0 101.04 102.08
22 101.04 101.04 101.04 101.04 101.04 100.0 101.04 101.04 101.04 101.04 101.04
23 102.08 102.08 98.96 98.96 98.96 98.96 102.08 101.04 101.04 101.04 101.04
24 100.0 100.0 95.83 97.92 96.88 96.88 100.0 98.96 100.0 100.0 0.0
25 101.04 102.08 98.96 98.96 96.88 97.92 101.04 100.0 101.04 101.04 101.04
26 101.04 102.08 100.0 100.0 98.96 98.96 100.0 101.04 101.04 101.04 101.04
27 103.13 103.13 102.08 100.0 101.04 101.04 102.08 101.04 103.13 102.08 101.04
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B.3 Dose to organs at risk
Details on the dose to OARs for PT and SBRT will be given here. Various OAR’s DMax , DThreshold
and DMean will be given here for all patients used in the study.
Table B.3.: SBRT DMax for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 17.0 4.25 16.0 4.75 0.5 6.25 26.75 4.5
2 0 2.75 16.75 3.5 2.75 5.5 26.75 2.5
3 7.5 8.5 17.5 7.0 0.25 7.75 10.0 26.5
4 0.25 5.5 10.25 5.5 0 5.0 26.25 3.5
5 8.25 10.25 12.75 9.75 0 26.25 26.25 9.25
6 6.0 2.5 23.75 3.5 0 4.5 26.25 3.5
7 0.25 7.0 19.25 6.0 9.75 8.25 4.75 25.75
8 12.5 8.75 13.75 14.0 3.5 24.75 26.75 11.5
9 11.25 9.75 22.75 11.0 0.25 19.25 25.75 26.0
10 15.0 9.25 13.0 10.75 0 27.25 27.75 27.5
11 12.0 2.75 0.25 2.25 0 4.25 26.25 1.75
12 0.0 4.75 0.0 7.0 7.75 9.75 25.75 5.25
13 3.25 6.25 11.0 4.5 0 3.5 4.25 26.5
14 0.0 3.75 9.25 4.0 4.75 5.5 2.25 26.0
15 0 3.75 0 5.75 0 0 26.0 5.0
16 2.5 2.0 0 3.75 4.75 18.0 10.0 26.25
17 0.25 8.25 0 11.5 7.25 26.25 26.25 6.75
18 0 2.5 0 3.5 2.25 0.0 2.25 26.0
19 0 8.5 0.75 6.0 4.25 22.75 26.0 5.0
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Table B.4.: SBRT DThreshold for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 9.75 3.5 7.87 3.75 0.0 4.75 0.75 0.25
2 0 2.0 10.0 1.5 1.67 3.25 0.0 0.0
3 6.0 7.5 5.25 3.25 0.0 5.67 0.0 0.0
4 0.0 4.75 3.75 2.75 0 3.5 0.0 0.0
5 6.0 8.25 0.96 1.0 0 11.75 0.0 0.0
6 4.0 2.25 5.0 1.11 0 1.75 0.0 0.0
7 0.0 6.5 11.5 3.25 5.5 6.0 0.0 0.0
8 9.75 7.25 10.75 11.0 2.62 18.25 1.75 1.69
9 8.5 8.5 12.25 6.75 0.0 12.5 0.0 0.0
10 10.25 8.5 7.25 6.25 0 10.5 0.0 0.25
11 5.75 2.5 0.33 0.25 0 1.5 0.0 0.0
12 0.0 4.0 0.0 0.5 5.5 4.5 0.0 0.0
13 1.75 5.5 4.25 3.25 0 2.25 0.0 0.0
14 0.0 3.5 0.42 2.0 2.25 2.75 0.0 0.0
15 0 3.25 0 1.25 0 0 0.0 0.0
16 0.0 1.5 0 0.25 2.82 5.25 0.0 0.0
17 0.0 7.0 0 3.5 4.9 6.25 0.0 0.0
18 0 2.25 0 1.87 1.44 0.0 0.0 0.0
19 0 7.5 0.0 1.75 2.25 5.0 0.0 0.0
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Table B.5.: SBRT DMean for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 1.96 0.52 6.5 0.92 0.11 1.31 3.88 0.7
2 0 0.28 5.53 0.43 0.41 0.97 1.46 0.23
3 2.48 2.27 2.83 4.08 0.06 2.43 0.9 2.9
4 0.06 0.81 3.02 0.77 0 1.08 1.88 0.49
5 1.49 0.66 3.8 1.18 0 2.38 1.79 0.61
6 1.34 0.19 6.1 1.22 0 1.57 1.3 0.2
7 0.07 0.7 6.08 1.07 1.81 1.65 0.69 2.88
8 6.4 2.02 6.33 4.65 0.92 5.75 8.82 2.24
9 3.57 1.66 2.57 1.8 0.1 1.68 3.05 2.95
10 4.72 1.2 2.65 2.97 0 3.45 5.4 5.15
11 1.52 0.38 0.17 0.26 0 0.3 1.65 0.2
12 0.02 0.26 0.03 0.7 1.85 0.4 1.44 0.3
13 0.77 1.18 2.16 1.68 0 0.48 0.6 3.62
14 0.03 0.27 0.78 0.55 1.01 0.76 0.22 1.52
15 0 0.49 0 1.12 0 0 0.7 0.09
16 0.06 0.25 0 0.49 1.14 1.49 0.37 2.29
17 0.08 1.69 0 1.15 1.94 1.51 2.39 0.4
18 0 0.27 0 0.58 0.51 0.04 0.06 0.38
19 0 0.75 0.13 0.62 1.0 0.73 1.4 0.28
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Table B.6.: PT DMax for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 11.75 0.0 24.0 0.25 0.0 3.75 26.0 0.75
2 0 0.0 25.25 0.0 0.0 0.25 26.5 0.0
3 7.5 0.25 9.75 7.25 0.0 7.75 7.5 27.25
4 0.0 3.25 13.5 0.25 0 4.0 25.5 1.0
5 10.0 6.0 10.25 3.75 0 26.75 26.75 0.25
6 0.0 0.0 25.25 0.0 0 0.0 26.5 0.0
7 0.0 7.0 22.25 0.0 0.0 0.0 0.0 26.25
8 6.5 7.75 15.5 1.0 1.0 20.75 31.5 8.25
9 0.0 0.5 6.25 0.0 0.0 4.25 25.75 25.5
10 13.5 0.0 16.0 0.25 0 25.25 26.75 26.0
11 14.5 0.0 0.0 0.0 0 0.0 26.25 0.0
12 0.0 0.0 0.0 0.0 0.0 0.25 26.25 0.0
13 0.0 0.0 0.0 0.0 0 0.0 0.0 26.5
14 0.0 0.0 8.0 0.0 0.0 0.0 0.0 25.5
15 0 0.0 0 0.0 0 0 25.75 0.0
16 0.25 0.0 0 0.0 0.0 18.25 0.75 26.0
17 0.0 0.5 0 9.0 0.5 25.75 26.0 0.0
18 0 0.0 0 0.0 0.0 0.0 0.0 25.75
19 0 0.25 0.25 0.0 0.0 17.75 26.5 0.0
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Table B.7.: PT DThreshold for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 8.25 0.0 7.75 0.0 0.0 0.75 0.0 0.0
2 0 0.0 13.75 0.0 0.0 0.0 0.0 0.0
3 3.5 0.0 1.0 0.0 0.0 0.42 0.0 0.0
4 0.0 2.0 5.25 0.0 0 0.75 0.0 0.0
5 2.5 1.75 0.0 0.0 0 14.0 0.0 0.0
6 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0
7 0.0 3.0 10.25 0.0 0.0 0.0 0.0 0.0
8 1.91 5.5 11.0 0.25 0.0 7.25 0.0 0.0
9 0.0 32.0 0.11 0.0 0.0 0.25 0.0 0.0
10 10.25 0.0 0.5 0.0 0 3.75 0.0 0.0
11 0.25 0.0 0.0 0.0 0 0.0 0.0 0.0
12 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
13 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0
14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15 0 0.0 0 0.0 0 0 0.0 0.0
16 0.0 0.0 0 0.0 0.0 0.25 0.0 0.0
17 0.0 0.25 0 0.0 0.0 5.5 0.0 0.0
18 0 0.0 0 0.0 0.0 0.0 0.0 0.0
19 0 0.0 0.0 0.0 0.0 0.25 0.0 0.0
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Table B.8.: PT DMean for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.53 0.0 3.67 0.01 0.0 0.08 3.46 0.03
2 0 0.0 4.32 0.0 0.0 0.01 1.7 0.0
3 0.49 0.02 0.56 0.91 0.0 0.51 0.12 2.5
4 0.0 0.17 3.58 0.0 0 0.09 1.35 0.06
5 0.45 0.03 0.47 0.22 0 2.24 0.61 0.0
6 0.0 0.0 2.96 0.0 0 0.0 1.58 0.0
7 0.0 0.11 2.11 0.0 0.0 0.0 0.0 2.97
8 0.6 0.68 2.25 0.06 0.06 1.08 6.0 0.36
9 0.0 0.05 0.06 0.01 0.0 0.03 1.71 1.24
10 1.16 0.0 0.5 0.01 0 0.68 3.45 3.55
11 0.06 0.0 0.0 0.0 0 0.0 2.26 0.0
12 0.0 0.0 0.0 0.0 0.0 0.0 1.03 0.0
13 0.0 0.01 0.01 0.0 0 0.0 0.0 2.14
14 0.0 0.0 0.28 0.0 0.0 0.0 0.0 1.88
15 0 0.01 0 0.01 0 0 0.9 0.0
16 0.0 0.0 0 0.0 0.0 0.16 0.0 1.88
17 0.0 0.03 0 0.15 0.03 1.29 2.55 0.0
18 0 0.0 0 0.0 0.0 0.0 0.0 0.4
19 0 0.01 0.01 0.0 0.0 0.07 1.49 0.0
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C Appendix to Chapter 4
C.1 Target coverage
Target coverage is displayed as CTV D99% in Table C.1. It was calculated for ITV, 4Dopt and
SBRT. For ITV and 4Dopt 4 different breathing periods were used.
Table C.1.: Target coverage for ITV, 4DOpt and SBRT as CTV D99%. ITV and 4Dopt used two
breathing periods: 3.6 and 5 s (Per 3s and Per 5s) and two starting phases: 0◦ and
90◦ (Ph0 and Ph90). All values are displayed as percentage of the planned dose.
Target
ITV 4Dopt
SBRTPer 3.6s Per 5s Per 3600s Per 5000s
Ph = 0 Ph = 90 Ph0 Ph90 Ph0 Ph90 Ph0 Ph90
1a 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04 100.0
1b 102.08 101.04 101.04 101.04 101.04 101.04 101.04 101.04 100.0
2a 101.04 101.04 102.08 101.04 101.04 98.96 98.96 102.08 106.25
2b 102.08 102.08 102.08 102.08 102.08 102.08 102.08 102.08 103.13
2c 101.04 101.04 101.04 100.0 101.04 102.08 102.08 101.04 104.17
2d 102.08 102.08 102.08 101.04 102.08 102.08 102.08 102.08 107.29
2e 101.04 101.04 101.04 101.04 101.04 101.04 101.04 102.08 108.33
3a 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04 101.04
3b 97.92 98.96 98.96 97.92 97.92 97.92 97.92 97.92 102.08
4a 69.44 63.89 65.74 64.81 72.22 69.44 68.52 71.3 66.67
4b 100.0 102.08 100.0 102.08 101.04 100.0 102.08 100.0 103.13
5a 98.96 100.0 101.04 100.0 100.0 100.0 100.0 100.0 101.04
5b 102.08 102.08 100.0 101.04 97.92 97.92 98.96 96.88 101.04
5c 96.88 94.79 94.79 95.83 92.71 94.79 93.75 94.79 98.96
5d 98.96 98.96 98.96 97.92 100.0 98.96 98.96 100.0 94.79
6a 88.54 89.58 88.54 90.63 85.42 87.5 85.42 85.42 69.79
6b 78.13 79.17 77.08 79.17 72.92 71.88 71.88 72.92 69.79
7a 102.08 102.08 102.08 102.08 98.96 98.96 98.96 98.96 101.04
7b 82.14 85.71 82.14 85.71 75.0 75.0 75.0 75.0 100.0
8a 100.0 100.93 100.0 100.0 100.0 99.07 99.07 100.93 105.56
8b 101.25 101.25 100.0 102.5 100.0 100.0 100.0 101.25 105.0
8c 100.0 100.0 100.0 99.07 97.22 99.07 100.0 100.0 106.48
8d 102.27 102.27 102.27 102.27 90.91 89.77 89.77 89.77 102.27
8e 102.5 102.5 102.5 102.5 91.25 92.5 91.25 92.5 101.25
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C.2 Dose to organs at risk
Details on the dose to OARs for ITV, 4Dopt and SBRT will be given here. Various OAR’s DMax ,
DThreshold and DMean will be for all patients used in the study.
Table C.2.: ITV DMax for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 7.0 0.0 0.0 3.0 26.0 26.0
2 11.0 0.0 12.0 0.0 0.0 23.0 26.0 26.0
3 5.0 7.0 14.0 1.0 1.0 20.0 26.0 7.0
4 25.0 8.0 23.0 20.0 3.0 4.0 26.0 29.0
5 22.0 1.0 0.0 1.0 0.0 3.0 29.0 1.0
6 17.0 5.0 17.0 2.0 0.0 8.0 27.0 29.0
7 7.0 0.0 9.0 7.0 0.0 8.0 9.0 26.0
8 28.0 5.0 21.0 7.0 7.0 28.0 30.0 25.0
Table C.3.: ITV DThreshold for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 8.0 0.0 2.0 0.0 0.0 2.0 0.0 0.0
3 2.0 5.0 8.0 0.0 0.0 6.0 0.0 0.0
4 4.0 6.0 17.0 3.0 0.0 2.0 0.0 0.0
5 2.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0
6 4.0 3.0 12.0 1.0 0.0 2.0 0.0 0.0
7 1.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0
8 14.0 3.0 9.0 2.0 4.0 12.0 0.0 1.0
Table C.4.: ITV DMean for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.0
2 1.0 0.0 1.0 0.0 0.0 0.0 3.0 3.0
3 0.0 1.0 2.0 0.0 0.0 1.0 4.0 0.0
4 1.0 1.0 6.0 1.0 0.0 0.0 2.0 1.0
5 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0
6 0.0 0.0 3.0 0.0 0.0 1.0 4.0 2.0
7 0.0 0.0 1.0 1.0 0.0 0.0 0.0 2.0
8 1.0 0.0 4.0 1.0 1.0 1.0 8.0 6.0
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Table C.5.: 4Dopt DMax for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 7.0 0.0 0.0 3.0 26.0 26.0
2 11.0 0.0 12.0 0.0 0.0 22.0 26.0 26.0
3 5.0 8.0 15.0 1.0 1.0 21.0 27.0 8.0
4 28.0 8.0 22.0 25.0 1.0 6.0 26.0 29.0
5 21.0 0.0 0.0 1.0 0.0 3.0 29.0 1.0
6 15.0 4.0 16.0 2.0 0.0 6.0 28.0 28.0
7 7.0 0.0 8.0 7.0 0.0 7.0 8.0 26.0
8 29.0 5.0 21.0 8.0 7.0 27.0 30.0 25.0
Table C.6.: 4Dopt DThreshold for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
2 8.0 0.0 2.0 0.0 0.0 2.0 0.0 0.0
3 2.0 5.0 8.0 0.0 0.0 6.0 0.0 0.0
4 5.0 6.0 17.0 4.0 0.0 3.0 0.0 0.0
5 1.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0
6 4.0 3.0 11.0 1.0 0.0 2.0 0.0 0.0
7 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0
8 13.0 3.0 9.0 2.0 3.0 11.0 0.0 0.0
Table C.7.: 4Dopt DMean for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.0
2 1.0 0.0 1.0 0.0 0.0 0.0 3.0 3.0
3 0.0 1.0 2.0 0.0 0.0 1.0 4.0 0.0
4 1.0 1.0 7.0 2.0 0.0 1.0 2.0 2.0
5 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0
6 0.0 0.0 3.0 0.0 0.0 1.0 4.0 2.0
7 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.0
8 1.0 0.0 3.0 1.0 1.0 1.0 8.0 5.0
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Table C.8.: SBRT DMax for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 11.0 10.0 23.0 11.0 0.0 19.0 26.0 26.0
2 15.0 9.0 13.0 11.0 0.0 27.0 28.0 28.0
3 13.0 9.0 14.0 14.0 4.0 25.0 27.0 12.0
4 29.0 8.0 18.0 26.0 3.0 17.0 27.0 30.0
5 23.0 3.0 0.0 6.0 0.0 6.0 26.0 4.0
6 21.0 11.0 15.0 14.0 1.0 14.0 26.0 26.0
7 8.0 9.0 18.0 7.0 0.0 8.0 10.0 27.0
8 31.0 13.0 16.0 12.0 8.0 31.0 32.0 25.0
Table C.9.: SBRT DThreshold for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 9.0 9.0 12.0 7.0 0.0 13.0 0.0 0.0
2 10.0 9.0 7.0 6.0 0.0 11.0 0.0 0.0
3 10.0 7.0 11.0 11.0 3.0 18.0 2.0 2.0
4 12.0 7.0 15.0 6.0 1.0 7.0 0.0 0.0
5 13.0 3.0 0.0 3.0 0.0 4.0 0.0 0.0
6 16.0 10.0 12.0 12.0 0.0 11.0 0.0 0.0
7 6.0 8.0 5.0 3.0 0.0 6.0 0.0 0.0
8 22.0 11.0 11.0 8.0 5.0 23.0 0.0 6.0
Table C.10.: SBRT DMean for various OARs. Values are in Gy.
Patient
Heart
Spinal Smaller
Esophagus Trachea Aorta
Left Right
Nr cord airways lung lung
1 4.0 2.0 3.0 2.0 0.0 2.0 3.0 3.0
2 5.0 1.0 3.0 3.0 0.0 3.0 5.0 5.0
3 6.0 2.0 6.0 5.0 1.0 6.0 9.0 2.0
4 4.0 2.0 6.0 3.0 1.0 2.0 3.0 3.0
5 4.0 1.0 0.0 1.0 0.0 1.0 6.0 1.0
6 6.0 2.0 4.0 5.0 0.0 4.0 6.0 4.0
7 2.0 2.0 3.0 4.0 0.0 2.0 1.0 3.0
8 10.0 3.0 8.0 4.0 3.0 6.0 10.0 9.0
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C.3 Organs at risk margins
Table C.11 shows the margins that were applied to OAR, before subtracting OAR plus margins
from CTV in patients with complex geometry.
Table C.11.: OAR margins used for subtraction from CTV for ITV, 4Dopt and SBRT.
Patient OAR
Margin (mm)
ITV 4Dopt SBRT
Patient 4
Smaller airways 2 2 1
Esophagus 0 0 1
Patient 5 Heart 0 0 2
Patient 6
Left lung Smaller airways 3 2 11
Right lung smaller airways 0 0 9
Patient 7
Esophagus 2 2 0
Stomach 0 0 1
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